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Abstract
Integrin receptor binding to extracellular matrix proteins generates intracellular signals via enhanced
tyrosine phosphorylation events that are important for cell growth, survival, and migration. This review
will focus on the functions of the focal adhesion kinase (FAK) protein-tyrosine kinase (PTK) and its
role in linking integrin receptors to intracellular signaling pathways. FAK associates with several
dierent signaling proteins such as Src-family PTKs, p130
Cas, Shc, Grb2, PI 3-kinase, and paxillin. This
enables FAK to function within a network of integrin-stimulated signaling pathways leading to the
activation of targets such as the ERK and JNK/mitogen-activated protein kinase pathways. Focus will
be placed on the structural domains and sites of FAK tyrosine phosphorylation important for FAK-
mediated signaling events and how these sites are conserved in the FAK-related PTK, Pyk2. We will
review what is known about FAK activation by integrin receptor-mediated events and also non-integrin
stimuli. In addition, we discuss the emergence of a consensus FAK substrate phosphorylation sequence.
Emphasis will also be placed on the role of FAK in generating cell survival signals and the cleavage of
FAK during caspase-mediated apoptosis. An in-depth discussion will be presented of integrin-stimulated
signaling events occurring in the FAK knockout ®broblasts (FAK
ÿ) and how these cells exhibit de®cits
in cell migration. FAK re-expression in the FAK
ÿ cells con®rms the role of this PTK in the regulation
of cell morphology and in promoting cell migration events. In addition, these results reinforce the
potential role for FAK in promoting an invasive phenotype in human tumors. # 1998 Elsevier
Science Ltd. All rights reserved.
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Interaction of cells with extracellular matrix (ECM) proteins generates intracellular signals
important for growth, survival, and migration. The integrin family of transmembrane receptors
have long been recognized for their structural roles in linking ECM proteins with the cellular
actin cytoskeleton in the regulation of cell shape and tissue architecture. Recent developments
within the ®eld of integrin biology have shown that integrin receptors can initiate signal
transduction events that aect many aspects of cell growth (for recent reviews see Schwartz et
al., 1995; Burridge and Chrzanowska-Wodnicka, 1996; Giancotti, 1997; Aplin et al., 1998). In
a variety of cell types, enhanced tyrosine phosphorylation of signaling proteins is a common
response to integrin receptor clustering after binding to ECM proteins. However, since
transmembrane integrin receptors do not possess catalytic activity, the signals initiated by
ECM-integrin interactions must be transduced into cells through the activation of integrin-
associated proteins. Whereas evidence is emerging that integrin receptors can cocluster with
(Miyamoto et al., 1996; Schneller et al., 1997) and aect the cellular response to growth factor
receptor protein-tyrosine kinases (PTKs) (for a review see Sastry and Horwitz, 1996), a variety
of nonreceptor PTKs such as the Abl, Syk, FAK and Src-family PTKs (for recent reviews see
Guan, 1997; Hanks and Polte, 1997; Parsons and Parsons, 1997; Schlaepfer and Hunter, 1998)
can be rapidly activated by integrin receptor clustering or cell binding to ECM proteins.
This review will focus on the functions of the focal adhesion kinase (FAK) and its role in
linking integrin receptors to intracellular signaling pathways. It should be emphasized that
integrins connect to a number of dierent signaling proteins and that FAK can be considered
as one part of this network. In adherent cell types, FAK colocalizes with integrin receptors at
cell-substratum contact sites termed focal adhesions and FAK was originally named as such
for its hypothesized role as the important PTK involved in forming these structures (Schaller et
al., 1992). Indeed, cellular focal adhesions contain structural proteins associated with the actin
cytoskeleton and signaling proteins that in many cases are modi®ed by tyrosine
phosphorylation. In addition, treatment of cells with tyrosine phosphatase inhibitors leads to
enhanced focal contact formation whereas pharmacological tyrosine kinase inhibitors prevent
their formation (for a review see Burridge et al., 1997). Although correlative evidence points to
a role for FAK in focal adhesion formation (for a review see Parsons, 1997), ®broblasts
isolated from the FAK knockout mouse (FAK
ÿ) exhibit enhanced focal contact formation in
cell culture supporting a role for FAK in the dynamic regulation of these structures (Ilic et al.,
1995b).
As will be discussed, FAK associates with a number of dierent signaling proteins which
enables this PTK to couple to a variety of dierent intracellular signaling pathways. Although
the exact mechanisms leading to FAK kinase activation are not well de®ned, enhanced FAK
tyrosine phosphorylation events are an important link between integrin receptors and the
activation of downstream targets such as the ERK and JNK/mitogen-activated protein kinase
cascades. FAK connections to phosphatidylinositol 30-kinase may provide an essential
anchorage-dependent survival signal in the prevention of cell apoptosis and in addition,
caspase cleavage of FAK during the initial stages of cell apoptosis can generate a FAK protein
fragment that can promote cell death. FAK also plays a role in early mammalian development
during the processes of gastrulation. Homozygous mutations in murine FAK result in
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migration defects in cell culture. This cellular phenotype seems to stem from an inability to
eciently remodel or turnover the contacts at the cell-substratum interface in the FAK
ÿ cells.
We will review what is known about the integrin-stimulated signaling events in the FAK
ÿ
®broblasts and the eects of either transient (Sieg et al., 1998) or stable (discussed herein) FAK
protein re-expression in these cells. Emerging evidence supports the hypothesis that FAK does
indeed play an important role in the regulation of focal contact structures with respect to cell
shape and during the processes of cell migration. With respect to human cancer, the
accumulated ®ndings on the role of FAK in the processes of cell survival and cell migration
suggest that elevated FAK expression in tumors of high invasive potential may directly
contribute to the metastatic phenotype.
2. Structural domains of FAK
2.1. FAK isoforms generated by alternative splicing
FAK is a nonreceptor and nonmembrane associated PTK which does not contain Src
homology 2 (SH2) or SH3 protein interaction domains. The centrally located kinase domain of
FAK is ¯anked by large N- and C-terminal noncatalytic domains (Fig. 1). FAK homologs
have been identi®ed in human (Whitney et al., 1993), mouse (Hanks et al., 1992), chicken
(Schaller et al., 1992), and frog (Hens and DeSimone, 1995) and they share over 90% amino
acid sequence identity. In addition, a Drosophila FAK cDNA has been isolated and it exhibits
a similar domain structure as other FAK homologs (R. Palmer, personal communication).
Several FAK isoforms can be produced as a result of the use of alternative promoters and
through alternative splicing (Fig. 1). For instance, chicken ®broblasts express an N-terminally
truncated form of FAK termed FRNK (FAK-related nonkinase), whose mRNA is generated
from a promoter located within an intron lying downstream of the catalytic domain (Schaller
et al., 1993). Alternatively-spliced mouse FAK mRNAs have been identi®ed that have
variations in kinase domain residues (Eide et al., 1995) and rat brain contains FAK transcripts
(termed FAK
+) encoding a 3 amino acid insertion (Pro±Trp±Arg) within the C-terminal
domain (Burgaya and Girault, 1996). An antigenically-distinct FAK isoform termed FAKB
also has been described (Kanner et al., 1994) however its existence has not been con®rmed by
DNA sequencing information.
These dierent isoforms may be important for the regulation of FAK biological activity,
since FRNK can act as a negative regulator of full-length FAK (Richardson and Parsons,
1996) and FAK
+ can be dierentially activated by speci®c cellular stimuli (Derkinderen et al.,
1996). Additional FAK alternatively-spliced isoforms termed FAK box 6, box 7 and box 28
yield proteins with amino acid insertions surrounding the FAK autophosphorylation site at
Tyr-397 (Burgaya et al., 1997) (see Fig. 1). The presence of boxes 6 or 7 within FAK yield
proteins that exhibit increased in vitro kinase activity potentially through subtle conformation
and changes as will be discussed in Section 3.3. Many of these FAK isoforms are speci®cally
expressed in brain tissues suggesting that neuronal FAK may exhibit speci®c and unique
properties.
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In ®broblasts, the localization of FAK with integrin receptors at cell substratum contact sites
is mediated by sequences within the tail of the C-terminal domain of FAK. This stretch of
0160 amino acids can function independently to localize fusion proteins to focal contact sites
(Hildebrand et al., 1993). Contained within the focal adhesion targeting domain are binding
sites for proteins such as paxillin and talin. Paxillin is an adaptor protein containing dierent
interaction domains such as a proline-rich site for SH3 domain binding, four N-terminal
domain LD motifs which contribute to FAK binding, and four zinc-®nger LIM domains which
are important for paxillin targeting to focal contacts (Brown et al., 1996). Talin is a structural
protein that can associate with b-integrin cytoplasmic tails. In vitro binding analyses have
Fig. 1. FAK structural features and alternate splice forms. (A) FAK contains a central kinase domain ¯anked by
large N- and C-terminal domains. Unde®ned residues within the FAK N-terminal domain may associate with
integrin receptors and the tail region of the FAK C-terminal domain contains residues important for focal adhesion
targeting (FAT). The major FAK autophosphorylation site is at Tyr-397. Alternate-spliced FAK isoforms (box 6, 7,
and 28) contain amino acid insertions surrounding the FAK Tyr-397. Other FAK isoforms include FRNK which is
the C-terminal noncatalytic domain of FAK and FAK
+ which contains a short 3 amino acid insertion as
indicated. Two Proline-rich regions in the FAK C-terminal domain are sites for SH3 domain-containing protein
binding. (B) As indicated, the FAT domain contains regions important for paxillin (PBS, paxillin binding sequences)
and talin binding.
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1995) (Fig. 1). Mutagenesis and in vitro binding analyses have identi®ed two regions ¯anking
the talin binding site in the FAT domain which are important for both FAK localization to
focal contacts and paxillin binding (Tachibana et al., 1995). These sites have been termed
paxillin binding sequences (PBS1 and PBS2). Interestingly, PBS2 shares sequence similarity to
a contiguous stretch of 22 amino acids in the structural protein vinculin which also binds to
paxillin in vitro (Wood et al., 1994).
Although it has been hypothesized that paxillin recruits FAK to focal contact sites
(Tachibana et al., 1995), other reports have shown FAK localization to integrin clusters/focal
adhesions in the absence of paxillin association (Hildebrand et al., 1995; Miyamoto et al.,
1995b). FAK also contains unde®ned sequences within its N-terminal domain that can bind
peptides derived from b-integrin cytoplasmic domains (Schaller et al., 1995) which may act to
stabilize FAK associations with integrins in focal contacts. Therefore, it is likely that multiple
protein binding interactions with proteins such as paxillin, talin, and integrins act to recruit
and stabilize FAK localization to focal contacts.
2.3. Comparisons with the FAK-related PTK, Pyk2
FAK and a second nonreceptor PTK variously called proline-rich tyrosine kinase 2 (Pyk2)
(Lev et al., 1995), cell adhesion kinase b (CAKb) (Sasaki et al., 1995), related adhesion focal
tyrosine kinase (RAFTK) (Avraham et al., 1995), or calcium-dependent protein-tyrosine kinase
(CADTK) (Yu et al., 1996) de®ne a new subfamily of nonreceptor PTKs. To avoid
nomenclature confusion, we will refer to this FAK-related protein as Pyk2 (Fig. 2). Pyk2 is
highly expressed in cells of the central nervous system and is also found in cells of
hematopoietic lineage. Pyk2 (112 kDa) is slightly smaller than FAK (119 kDa), both proteins
contain unique sequences within the ®rst 100 amino acid residues, and Pyk2 and FAK share
045% overall sequence similarity (Fig. 2). Pyk2 and FAK sequence conservation is maximal
within the central kinase domains and surrounding the conserved tyrosine phosphorylation
sites which are also binding sites for SH2 domain containing proteins (Table 1). The C-
terminal domain regions of FAK and Pyk2 also contain two conserved proline-rich domains
which are also binding sites for SH3 domain containing proteins (Fig. 2 and Table 1). Pyk2
mRNA transcripts are subject to alternative splicing in the region between the two proline-rich
domains yielding a Pyk2-variant with a 42 amino acid deletion (Dikic and Schlessinger, 1998;
Li et al., 1998; Xiong et al., 1998).
The Pyk2 C-terminal tail region contains consensus paxillin binding sequences (PBS1, 875±
894 and PBS2, 985±999) (Fig. 2) and Pyk2 can associate with paxillin (Salgia et al., 1996a; Li
and Earp, 1997), or with the paxillin-related proteins Hic-5 (Matsuya et al., 1998), or with
leupaxin (Lipsky et al., 1998) in lysates from a variety of cell types. Although there is strong
evidence to support the association of Pyk2 with paxillin, immuno¯uorescent localization
studies have shown that both endogenous Pyk2 (Sasaki et al., 1995; Matsuya et al., 1998; Sieg
et al., 1998; Zheng et al., 1998) or recombinant Pyk2 (Schaller and Sasaki, 1997) only weakly
associate with focal contacts in adherent cell types whereas paxillin exhibits strong localization
to these structures. Interestingly, the Pyk2 C-terminal domain (sequences related to FRNK)
strongly localized to focal contacts when exogenously-expressed in chicken ®broblasts (Schaller
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achieved by swapping the Pyk2 C-terminal domain with that of the FAK C-terminal domain
(Zheng et al., 1998). These results would suggest that 1) the FAK and Pyk2 C-terminal
domains are not equivalent in their abilities to target proteins to focal contacts and 2) that
paxillin binding may be sucient to promote localization to focal adhesions, but in the context
of full-length Pyk2, it may not be enough to over-ride other potential protein binding
interactions limiting the amount of Pyk2 localized to focal contact structures in cells.
Fig. 2. FAK and Pyk2 sequence comparisons. The central kinase domains, regions surrounding phosphorylation
sites (P), and proline-rich regions (Pro-1, Pro-2) show a high degree of sequence similarity between FAK and Pyk2.
The six sites of FAK tyrosine phosphorylation and the analogous sites in Pyk2 are indicated. FAK Tyr-397 and
Pyk2 Tyr-402 are sites for Src family PTK SH2 domain binding. The FAK Tyr-925 and Pyk2 Tyr-881 are sites for
Grb2 SH2 domain binding. FAK exhibits a focal adhesion targeting domain in its C-terminal part. Although Pyk2
does not have contain a complete FAT domain as in FAK, Pyk2 contains conserved paxillin binding sequences in
the C-terminal tail region. The regional sequence similarities between FAK and Pyk2 are also highlighted.
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Analyses of FAK activation events have shown that integrin-stimulated FAK tyrosine
phosphorylation is complex and occurs at six or more sites in vivo (Calalb et al., 1995;
Schlaepfer and Hunter, 1996). Two sites within the FAK N-terminal domain (Tyr-397 and
Tyr-407), two sites within the kinase domain activation loop (Tyr-576 and Tyr-577), and two
sites within the C-terminal domain (Tyr-861 and Tyr-925) are phosphorylated in vivo (Fig. 2
and Table 1). Four of the six FAK tyrosine phosphorylation sites (Tyr-397, 576, 577, and 925)
are conserved at analogous positions in Pyk2 (Tyr-402, 579, 580, and 881). When expressed in
bacteria, recombinant FAK exhibits phosphorylation at Tyr-397 and therefore this site is a
bona ®de autophosphorylation site (Calalb et al., 1995). The motif surrounding FAK Tyr-397
(pTyr±Ala±Glu±Ile motif) ®ts the consensus for a Src-family SH2 domain binding site and
numerous studies have shown that the phosphorylation of this site regulates Src-family PTK
association with FAK in vivo (for a review see Schwartz et al., 1995).
The other FAK tyrosine phosphorylation sites have been shown to be preferentially trans-
phosphorylated by Src-family PTKs in vivo (Calalb et al., 1995, 1996; Schlaepfer and Hunter,
1996). Phosphorylation of FAK Tyr-567/577 in the activation loop of the kinase domain is
required for maximal FAK kinase activity (Calalb et al., 1995) and phosphorylation of FAK
Tyr-925 (pTyr±Glu±Asn±Val) creates a SH2 binding site for the Grb2 small adaptor protein
(Schlaepfer et al., 1994) (Table 1). Grb2 also has been shown to bind to activated Pyk2 (Lev et
al., 1995; Li et al., 1996a) and mutation of the equivalent Tyr-881 site (pTyr±Leu±Asn±Val) in
Pyk2 disrupts Grb2 binding (Felsch et al., 1998). As will be discussed in Section 4.1, direct
Grb2 binding to FAK or Pyk2 is one of several signaling pathways contributing to the
activation of downstream targets such as the ERK2/MAP kinase cascade. It should be also
emphasized that FAK exhibits a high level of serine phosphorylation at multiple-sites in vivo,
but the biological signi®cance of these events has not been determined (Calalb et al., 1995;
Schlaepfer and Hunter, 1996; Richardson et al., 1997b).
Another conserved feature of Pyk2 and FAK is the presence of two proline-rich motifs
within the C-terminal domain which are sites for SH3-mediated binding interactions. The SH3
domain of the large adaptor protein p130
Cas binds directly to the ®rst proline-rich motif
(residues 711±717) of FAK (Polte and Hanks, 1995; Harte et al., 1996) and further
Table 1
Conservation of SH2 and SH3 binding sites in FAK and Pyk2
Site in FAK FAK motif Site in Pyk2 Pyk2 Motif Kinase Function
Tyr-397 YAEI Tyr-402 YAEI FAK/Pyk2 Src-family PTK SH2 binding
Tyr-407 YTMP N/A N/A Src PTKs unknown
Tyr-576/577 STYYKAS Tyr-579/580 EDYYKAS Src PTKs regulatory/kinase activation loop
Tyr-861 YQPV N/A N/A Src PTKs unknown
Tyr-925 YENV Tyr-881 YLNV Src PTKs Grb2 SH2 binding site
Pro-712/713 APPKPSRPG Pro-714/715 PPPKPSRPK N/A p130
Cas SH3 binding site
Pro-876/877 PPKKPPRPG Pro-859/860 PPQKPPRLG N/A p130
Cas/Graf SH3 binding sites
Consensus p130
Cas SH3 binding motif (P-X-K-P-X-R) is underlined.
D.D. Schlaepfer et al. /Progress in Biophysics & Molecular Biology 71 (1999) 435±478 441mutagenesis studies have shown that the second proline-rich motif (residues 872±879) also
contributes to p130
Cas binding to FAK (Polte and Hanks, 1997). Pyk2 and p130
Cas also
associate (Astier et al., 1997b) and upon comparison of the two proline-rich domains from
both FAK and Pyk2, a consensus p130
Cas SH3 binding motif can be deduced (Pro-X±Lys±
Pro-X±Arg) (see Table 1). Another SH3 domain-containing protein that binds to both FAK
and Pyk2 is the GTPase-activating protein, Graf (Hildebrand et al., 1996; Ohba et al., 1998).
In vitro binding assays indicate that the SH3 domain of Graf may prefer the second proline-
Fig. 3. Proteins associated with FAK. A variety of dierent signaling proteins have been shown to directly associate
with FAK as indicated. It is possible that dierent combinations of proteins may aect the involvement of FAK in
dierent signaling pathways. Namely, direct Grb2 or Shc binding to FAK and the indirect association of the SOS
GDP-GTP exchange factor for Ras with Grb2 can link FAK to the activation of the Ras-ERK2/MAP kinase
pathway. FAK is also linked to other signaling pathways through the association and phosphorylation of p130
Cas
which promotes Crk and Nck adaptor protein binding to p130
Cas. The direct binding of paxillin and its association
with the protein tyrosine phosphatase PTP-PEST may be important for the dynamic regulation of integrin-
stimulated cycles of phosphorylation and dephosphorylation. N-terminal FAK domain association with integrin
cytoplasmic domains or talin binding to the FAK C-terminal domain may be important for the regulation of FAK
by integrins. The p85 subunit of PI 3-kinase binding to FAK and FAK-associated PI 3-kinase activity may be
important for FAK-mediated cell survival signals. The roles of CAP and Graf protein binding to FAK have not
been fully determined.
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Cas binding to FAK has been linked to
integrin-stimulated signaling and migration events (discussed in Sections 4.4 and 5.2), the role
for Graf and other FAK-associated proteins such as CAP (Ribon et al., 1998) have not been
determined.
In summary, since the SH2 and SH3 binding sites on FAK and Pyk2 are conserved, a
reasonable assumption is that signaling through either Pyk2 or FAK will involve these
common sites and may involve a common group of interacting proteins. As shown in Fig. 3,
FAK can associate with a number of dierent signaling, adaptor, as well as structural proteins.
It is FAK kinase activity and autophosphorylation at Tyr-397 which regulates the direct
binding of signaling proteins such as Src-family PTKS, the p85 subunit of phosphatidylinositol
3-kinase (Chen et al., 1996), and the Shc adaptor protein (Schlaepfer et al., 1998). Src-family
PTK phosphorylation of FAK at secondary sites regulates the direct binding of Grb2 at Tyr-
925 and the FAK-mediated enhancement of Src-family PTK activity is dependent upon FAK
kinase activity (Schlaepfer et al., 1997). As will be discussed later, a number of FAK-enhanced
signaling events are dependent on FAK autophosphorylation at Tyr-397. However, FAK
kinase activity may not be essential for all FAK functions. Overexpression of kinase-inactive
FAK has been shown to promote Chinese hamster ovary cell migration (Cary et al., 1996) and
kinase-inactive FAK can function to promote FceRI receptor-stimulated mast cell secretion
events (Hamawy et al., 1997). Since proteins such as paxillin, p130
Cas, and Graf bind to FAK
in a phosphorylation-independent manner, it is quite possible that FAK may also function in a
kinase-independent manner as an adaptor or linker protein in intracellular signal transduction
pathways.
2.5. Emerging consensus of FAK substrate phosphorylation sites
Although the exact manner in which FAK may function as a scaolding protein has not
been determined, proteins such as paxillin and p130
Cas are also considered targets for FAK
transphosphorylation. In many instances, cell stimulation leads to parallel increases in both
FAK and paxillin tyrosine phosphorylation with the implication being that FAK activation
may lead to increased paxillin phosphotyrosine (pTyr) levels. In vitro, FAK isolated from
mammalian cell lysates can phosphorylate paxillin at two sites, Tyr-31 and Tyr-118 (Bellis et
al., 1995; Schaller and Parsons, 1995). Signi®cantly, this FAK-dependent phosphorylation of
paxillin required the integrity of the autophosphorylation/Src SH2 binding site at Tyr-397 (see
Table 2). Since Phe-397 FAK exhibits signi®cant kinase activity in vitro (Schaller et al., 1994;
Calalb et al., 1995) but does not associate with Src-family PTKs, and since paxillin is a good
substrate for activated Src (Thomas et al., 1995), it is possible that phosphorylation of paxillin
may be mediated in part by FAK-associated Src-family PTK activity.
Similar to paxillin, a number of studies have documented increased p130
Cas pTyr levels
which parallel that of FAK after integrin stimulation of cells. Overexpression studies with Phe-
397 FAK have shown that FAK may preferentially phosphorylate either Tyr-762 or Tyr-764
within the p130
Cas (YDYVHL) sequence (Tachibana et al., 1997) (Table 2). Signi®cantly, this
region has been shown to be important for Src SH2 binding to p130
Cas (Nakamoto et al.,
1996). A model has been suggested that FAK may initiate integrin-mediated p130
Cas tyrosine
phosphorylation (Tachibana et al., 1997), leading to the recruitment of Src-family PTKs to
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Cas and the further Src-family PTK phosphorylation of p130
Cas within the substrate
domain. However, in cells de®cient for Src-family PTKs, p130
Cas is not detectably
phosphorylated even though FAK becomes activated and tyrosine phosphorylated after
integrin stimulation (Vuori et al., 1996; Hamasaki et al., 1996; Sakai et al., 1997). These results
suggest that it may be a complex of FAK and Src-family PTKs which leads to increased
p130
Cas tyrosine phosphorylation events.
Interestingly, stable expression of a fragment encompassing the SH3 and SH2 domains of
c-Src (Src 1±298) in Src-knockout cells promoted the enhanced FAK-mediated binding to and
phosphorylation of p130
Cas (Schlaepfer et al., 1997). Under these conditions, Src 1±298 acted
as an adaptor protein to facilitate a linkage between FAK and p130
Cas. In the Src 1±298
expressing cells, FAK phosphorylated p130
Cas at a number of dierent sites; some of which
facilitated the Nck adaptor protein binding to p130
Cas (Schlaepfer et al., 1997) (Fig. 3 and
Table 2). In comparing the known sites phosphorylated by FAK, a consensus motif can be
assembled (Table 2). It is reasonable to consider that an optimal FAK phosphorylation
recognition sequence may be its own autophosphorylation site (Glu±Thr±Asp±Asp±pTyr).
Accordingly, a clustering of glutamate or aspartate acidic residues in the +4 to +1 positions
precede the phosphorylated tyrosine residue in the FAK substrate proteins (Table 2). This
FAK consensus is similar to that determined for other nonreceptor tyrosine kinases. However,
there is no obvious selectivity for a hydrophobic residue immediately preceding the
phosphorylated tyrosine site as was determined for Abl and Src-family PTKs (Songyang et al.,
1995).
In some instances, such as the FAK-mediated phosphorylation of Shc at Tyr-317 (Schlaepfer
et al., 1998), the reactions are facilitated by the direct Shc SH2 domain binding to the FAK
autophosphorylation site at Tyr-397 (D. Schlaepfer, unpublished results). In addition, since
FAK kinase activity is important for the FAK-enhanced elevation of c-Src PTK activity after
integrin stimulation of cells (Schlaepfer and Hunter, 1997), it is interesting to speculate whether
this may involve the transphosphorylation of c-Src at Tyr-417 in the kinase activation loop
(Glu±Asp±Asn±Glu±pTyr). In this manner, since Src family PTKs can phosphorylate FAK
within the kinase activation loop to promote maximal FAK kinase activity (Calalb et al.,
Table 2
Emerging consensus of FAK substrate phosphorylation sites
FAK Substrate Site Motif Observations/function
Autophosphorylation Tyr-397 ETDDY Src-family PTK SH2 binding (YAEI)
Paxillin Tyr-31 EETPY dependent on FAK Tyr-397
Paxillin Tyr-118 EEHVY dependent on FAK Tyr-397
Shc Tyr-317 DDPSY phosphorylated by Phe-397 FAK
p130
Cas Tyr-762 WMEDY phosphorylated by Phe-397 FAK
p130
Cas Tyr-764 EDYDY phosphorylated by Phe-397 FAK
p130
Cas Tyr-332
a EQDEY Crk/Nck SH2 binding site (YDTP)
p130
Cas Tyr-460
a AEDVY Crk/Nck SH2 binding site (YDVP)
c-Src Tyr-417
b EDNEY regulatory/kinase activation loop
a Putative phosphorylation sites within p130
Cas `substrate domain'.
bPotential mechanism of FAK-enhanced c-Src
PTK activation.
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Non-integrin-mediated stimuli which enhance FAK tyrosine phosphorylation levels
Stimulus Cell type Observations References
Phorbol 12-myristate 13-
acetate (PMA)
murine ®broblasts dependent on PKC
activation
(various)
Bovine serum Swiss 3T3 ®broblasts stress ®ber and focal
contact formation
(Chrzanowska-Wodnicka
and Burridge, 1994)
Lysophosphatidic acid Swiss 3T3 ®broblasts independent of PKC or
Ca
2+ pathways
(Seuerlein and Rozengurt,
1995)
Activated Rho Swiss 3T3 ®broblasts dependent upon actin
cytoskeleton
(Flinn and Ridley, 1996)
Bombesin Swiss 3T3 ®broblasts rapid response (seconds) (Zachary et al., 1992)
Swiss 3T3 ®broblasts blocked by rho p21
inhibition
(Rankin et al., 1994)
prostate carcinoma cells stimulated FAK co-
immunoprecipitation with
b1, b3, and b5-integrins
(Aprikian et al., 1997)
Swiss 3T3 ®broblasts increased FAK kinase
activity dependent upon
intact cytoskeleton and cell
adherence
(Rodriguez-Fernandez and
Rozengurt, 1998)
Bradykinin Swiss 3T3 ®broblasts dependent upon PKC or
Ca
2+ pathways
(Leeb-Lundberg et al.,
1994)
Sphingolipid metabolites Swiss 3T3 ®broblasts requirement of Rho
signaling pathway
(Seuerlein and Rozengurt,
1995)
Swiss 3T3 ®broblasts not blocked by
wortmannin
(Sasaki et al., 1996)
Anandamide rat hippocampal slices actions through inhibition
of adenylyl cylase and
PKA
(Derkinderen et al., 1996)
Cholecystokinin pancreatic acinar cells dependent on cytoskeleton
and p21rho activity
(Garcia et al., 1997)
Angiotensin II vascular smooth muscle
cells
rapid response (seconds) (Polte et al., 1994)
Platelet-activating factor human endothelial cells inhibited by calphostin C (Soldi et al., 1996)
Muscarinic m3 receptors
(carbachol)
transfected HEK cells dependent on cellular
integrin engagement and
reduced by PKC inhibitors
(Slack, 1998)
Ga12 and Ga13 transfected HEK cells dependent on cytoskeleton
and p21
rho activity
(Needham and Rozengurt,
1998)
Platelet-derived growth
factor (PDGF)
Swiss 3T3 ®broblasts maximal at low
concentrations (1±5 ng/ml)
and dependent on the actin
cytoskeleton
(Rankin and Rozengurt,
1994)
vascular smooth muscle
cells
2.5 ng/ml stimulates
paxillin tyrosine
phosphorylation and cell
migration
(Abedi et al., 1995)
(continued on next page)
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Stimulus Cell type Observations References
Platelet-derived growth
factor (PDGF)
porcine aortic
endothelial cells
inhibited by wortmannin
and blocked by Phe-740/
751 mutations in PDGF
receptor
(Rankin et al., 1996)
rat mesangial cells
grown in 3D culture
stimulated collagen gel
contraction which was not
aected by MEK inhibitor
(Zent et al., 1998)
Hepatocyte growth factor
(HGF)
oral squamous
carcinoma cell lines
transient response inhibited
by cell pretreatment with
herbimycin A
(Matsumoto et al., 1994)
Macrophage colony-
stimulating factor
human monocytes stimulates Grb2 SH2
domain binding to FAK
(Kharbanda et al., 1995)
Insulin-like growth factor
(IGF-1)
human neuroblastoma
cells (SH-SY5Y)
IGF-1 promoted
lamellipodia extension and
paxillin tyrosine
phosphorylation
(Leventhal et al., 1997)
Insulin transfected Rat-1
®broblasts
direct insulin receptor
phosphorylation of FAK
only in suspended cells
(Baron et al., 1998)
Vascular endothelial
growth factor (VEGF)
endothelial cells
(HUVECs)
dependent upon
cytoskeleton and reduced
in presence of PKC
inhibitors
(Abedi and Zachary, 1997)
Steel factor human erythroleukemic
cell line (TF-1)
integrin-dependent and
enhanced the rate of cell
spreading on ®bronectin
(Takahira et al., 1997)
Growth hormone transfected Chinese
hamster ovary cells
requires Pro-rich box 1 of
GH receptor and
stimulates FAK association
with JAK2
(Zhu et al., 1998)
Hyaluronan mediated by
RHAMM receptor
ras-transformed 10T1/2
®broblasts
rapid, blocked by
herbimycin A, and cells
acquire motile phenotype
(Hall et al., 1994)
IgE receptor (FceRI) mast cell line RBL-2H3 requires cell adherence (Hamawy et al., 1993)
3B6 variant of RBL-
2H3 mast cells
FAK Tyr-397 and kinase
activity are not needed for
enhanced histamine release
(Hamawy et al., 1997)
Amyloid b peptide neuroblastoma cells stimulates Fyn PTK
association with FAK
(Zhang et al., 1996a)
requires cytoskeleton and
PKC activity
(Zhang et al., 1996b)
Cyclic stretching (1 Hz) rat mesangial cells rapid within 10 min (Hamasaki et al., 1995)
human umbilical
endothelial cells
morphological cell changes
blocked by herbimycin A
and FAK antisense
treatments
(Naruse et al., 1998)
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(Schlaepfer et al., 1994) may mutually lead to the maximal activation of both PTKs.
3. FAK activation events
3.1. Non-integrin stimuli that enhance FAK or Pyk2 tyrosine phosphorylation
FAK colocalizes with integrin receptors at cell-substratum contact sites in ®broblasts, and its
PTK activity is enhanced by cellular binding to extracellular matrix proteins. In consequence,
FAK has been proposed to play a central role in integrin-stimulated signaling events. However,
a number of other cellular stimuli that generate signals through either G-protein linked
receptors, transmembrane growth factor receptors, or through unknown mechanisms can
Table 3 (continued)
Stimulus Cell type Observations References
Hydrodynamic shear stress
(12 dyn/cm
2)
bovine aortic
endothelial cells
FAK Tyr-397 is important
for stimulated signals to
ERK2 and JNK1
(Li et al., 1997a,b)
Neural cell adhesion
molecule clustering
transfected COS-7
®broblasts
Src-family mediated
association of FAK with
the NCAM-140 receptor
(Beggs et al., 1997)
Glutamate rat hippocampal slices membrane depolarization-
induced activation blocked
by PKC inhibitors
(Siciliano et al., 1996)
K-252a inhibitor neuroblastoma cell line
SH-SY5Y
increased FAK kinase
activity and independent of
integrin-matrix interaction
(Maroney et al., 1995)
RANTES human CD4
+ T cells rapid activation of FAK
kinase activity
(Bacon et al., 1996)
P-selectin human peripheral blood
lymphocytes
increased paxillin tyrosine
phosphorylation with cell
attachment to ligand
(Haller et al., 1997)
Prolactin human breast
carcinoma cells
maximal at 5 ng/ml and
results in increased paxillin
tyrosine phosphorylation
(Canbay et al., 1997)
Hydrogen peroxide human glioblastoma cell
line (T98G)
FAK antisense treatment
led to higher levels of
peroxide-induced cell death
(Sonoda et al., 1997)
Human papillomavirus
type 18
human genital epithelial
cells
increased FAK activity,
paxillin tyrosine
phosphorylation and
®bronectin deposition
(McCormack et al., 1997)
Urokinase-type
plasminogen activator
receptor (uPAR)
bovine aortic
endothelial cells
correlation between FAK
and ERK2 activation
(Tang et al., 1998)
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Non-integrin-mediated stimuli which enhance Pyk2 tyrosine phosphorylation levels
Stimulus Cell Type Observations References
Calcium ionophores various inhibited by extracellular
EGTA
(various)
Phorbol 12-myristate 13-
acetate (PMA)
various inhibited by intracellular
calcium chelation,
calphostin C, and
cytochalasin D
(various)
KCl membrane
depolarization
PC12 cells rapid (seconds) and
dependent upon
extracellular calcium
(Lev et al., 1995)
rat hippocampal slices blocked by PKC inhibitors (Siciliano et al., 1996)
Thrombin human megkaryocytic cell
line (CMK)
cells in suspension
exhibited morphological
changes after stimulation
(Avraham et al., 1995)
human platelets not dependent upon
integrin GPIIb-IIIa but
inhibited by cytochalasin D
(Raja et al., 1997)
Tumor necrosis factor a PC12 and HL-60 cells not dependent on calcium
signals
(Tokiwa et al., 1996)
Osmolarity stress HL-60 cells dependent on calcium
signals
(Tokiwa et al., 1996)
smooth muscle cells dependent upon cell
adhesion costimuli
(Zheng et al., 1998)
Bradykinin PC12 cells not blocked by pertussis
toxin
(Dikic et al., 1996)
Lysophosphatidic acid PC12 cells blocked by pertussis toxin
but not dependent on
extracellular calcium
(Dikic et al., 1996)
Angiotensin II and
thapsigargin
rat liver epithelial cell lines
(WB and GN4)
rapid (seconds) and
correlated with JNK
activation
(Yu et al., 1996; Li et al.,
1997a,b)
T cell receptor activation jurkat and H9 T cell lines rapid within 1 min and
promotes Fyn and Grb2
binding to Pyk2
(Ganju et al., 1997)
mouse thymocytes not blocked by
extracellular EGTA and
dependent upon Fyn PTK
activity
(Qian et al., 1997)
Stem cell factor CMK cells mediated by a PKC-
dependent pathway
(Hiregowdara et al., 1997)
Vascular endothelial
growth factor (VEGF)
human Kaposi's sarcoma
cells
rapid and transient
activation
(Liu et al., 1997a)
Basic ®broblast growth
factor (bFGF)
human bone marrow
endothelial cells
rapid and transient
activation
(Liu et al., 1997b)
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have been shown to aect FAK kinase activity directly whereas others may activate another
PTK leading to the indirect elevation of FAK tyrosine phosphorylation. In many cases, such
as those of G-protein-coupled agonists, the events leading to increased FAK tyrosine
phosphorylation have been shown to be dependent upon the activity of the small GTP binding
protein p21 Rho (Needham and Rozengurt, 1998). It is not known what pathways downstream
of Rho are connected to FAK or whether the Rho eects are mediated through changes in the
actin cytoskeleton. However, one consistent observation has emerged from these studies of
non-integrin stimulated FAK tyrosine phosphorylation events. Namely, they are inhibited
when cells are incubated in the presence of cytochalasin D, a toxin which binds to the barbed
ends of actin ®laments and prevents actin polymerization.
A variety of cellular stimuli can also aect the level of Pyk2 tyrosine phosphorylation in cells
(Table 4). Many of these factors are the same as those shown to in¯uence FAK tyrosine
phosphorylation whereas others such as cell depolarization, osmolarity stress, or calcium
ionophore treatment activate Pyk2 to a greater extent in cells which express both FAK and
Pyk2 (Lev et al., 1995; Hiregowdara et al., 1997; Zheng et al., 1998). This dierence between
Table 4 (continued)
Stimulus Cell Type Observations References
Chemokine CCR5 ligands DU6 CD4
+ T cells rapid, transient and
inhibited by pertussis toxin
(Davis et al., 1997)
alternate-spliced Pyk2-H is
activated by both antigen
and chemokine stimuli
(Dikic and Schlessinger,
1998)
transfected pre-B
lymphoma cells
Pyk2-enhanced signaling to
JNK and increased paxillin
pTyr levels
(Ganju et al., 1998)
human monocytes cell adhesion and
cytoskeletal integrity are
required for maximal
stimulation
(Li et al., 1998)
IgE receptor (FceRI) mast cell line RBL-2H3 dependent upon Syk PTK
activation and dependent
upon cell adhesion
(Okazaki et al., 1997)
PDGF smooth muscle cells slow kinetics and
dependent on calcium
signals
(Brinson et al., 1998)
Interleukin-2 (IL-2) human peripheral blood
lymphocytes
dependent on JAK PTK
activation and involved in
IL-2-induced cell growth
(Miyazaki et al., 1998)
Macrophage colony-
stimulating Factor-1
human monocytic cell line
THP1
association of p85 and PI-3
kinase activity with Pyk2
(Hatch et al., 1998)
Fluoroaluminate mouse osteoblastic cells stimulated association with
Src PTKs
(Jeschke et al., 1998)
Muscarinic acetylcholine
receptor
transfected HEK cells carbachol-stimulated c-Src
and Grb2 binding to Pyk2
(Felsch et al., 1998)
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and thus Pyk2 is also known as CADTK, the calcium-dependent tyrosine kinase. However, it
needs to be re-emphasized that these calcium-mediated signals can also stimulate changes in
FAK tyrosine phosphorylation, albeit at lower levels than Pyk2 (Siciliano et al., 1996).
Calcium signals leading to enhanced Pyk2 tyrosine phosphorylation can be generated by the
in¯ux of extracellular calcium through voltage-gated calcium channels (Lev et al., 1995;
Tokiwa et al., 1996) or through calcium release from intracellular stores (Yu et al., 1996).
Although the mechanistic connections between these calcium signals and enhanced Pyk2
tyrosine phosphorylation are not well de®ned, one possibility is that it may involve unique
interactions of the Pyk2 N-terminal domain with putative calcium binding proteins.
3.2. FAK connections to b-integrin cytoplasmic domains
Increased tyrosine phosphorylation of intracellular proteins is one of the earliest responses
stimulated by integrin receptor activation when cells contact matrix proteins such as
®bronectin. Since transmembrane integrin receptors lack catalytic activity and null mutations
in both the murine ®bronectin (FN) and FAK genes result in similar early embryonic lethal
phenotypes, it has been proposed that FAK activation is important for FN-mediated signal
transduction events (for a review see Ilic et al., 1997). FAK colocalizes to sites of integrin-
receptor clustering and attention has been focused on the linkage between integrin cytoplasmic
domains and increased FAK tyrosine phosphorylation. Initial observations found that either
direct clustering of b1 integrins could stimulate FAK tyrosine phosphorylation and that
naturally occurring genetic mutations in residues of the b3 cytoplasmic domain disrupted the
integrin linkage to increased FAK tyrosine phosphorylation events (for a review see (Schwartz
et al., 1995). Our focus will be on b1 and b3 integrins, however evidence is emerging that a-
integrin cytoplasmic domains also can aect the regulation of FAK tyrosine phosphorylation
events as well (Leong et al., 1995).
Although integrins heterodimerize in a/b pairs, single subunit chimeras of the b1o rb3
cytoplasmic domain fused to the transmembrane-extracellular domain of non-integrin cell
surface receptors can promote increased FAK tyrosine phosphorylation in mammalian cells
(Akiyama et al., 1994; Lukashev et al., 1994). As shown in Fig. 4, the cytoplasmic domains of
the b1 and b3 integrins share regions of sequence similarity and peptides derived from the
juxtamembrane region of these cytoplasmic domains can bind to the N-terminal domain of
FAK in vitro (Schaller et al., 1995). However, an alternate spliced version of the b3 tail region
failed to stimulate FAK tyrosine phosphorylation (Akiyama et al., 1994) and the
juxtamembrane region involved in FAK binding has been shown to be neither required nor
sucient to stimulate FAK tyrosine phosphorylation in intact cells (Tahiliani et al., 1997). It is
the tail region of the b1 integrin cytoplasmic domain which is required for the recruitment of
FAK to integrin clusters (Lewis and Schwartz, 1995) and an alternate spliced version of the b1
tail (termed b1B) does not stimulate FAK tyrosine phosphorylation and acts as a dominant-
negative integrin to inhibit cell spreading and focal adhesion formation (Retta et al., 1998).
Although evidence is emerging that phosphorylation of the conserved b1/b3 tyrosine residues is
important for the regulation of integrin receptor ligand avidity (Blystone et al., 1997; Sakai et
al., 1998), recent studies have shown that it may be a particular secondary structure and not
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b3-mediated stimulation of FAK tyrosine phosphorylation (Tahiliani et al., 1997; Schaner-
Reckinger et al., 1998).
Unfortunately, a clear model of the b-integrin connections to FAK has not emerged and
events in addition to integrin activation may also be required to stimulate maximal FAK
activation (Lyman et al., 1997). Signi®cantly, the b3 and b1 integrin cytoplasmic tails also
associate with other proteins such as talin and a-actinin (Fig. 4) and therefore integrin
connections to FAK may be indirect and mediated by the binding of other integrin-associated
proteins. In summary, these studies are consistent with some sort of direct regulation of FAK
tyrosine phosphorylation by integrin receptor clustering, with the b subunit playing an
important role. FAK activation at sites of integrin clustering may involve multiple protein
interactions and be dependent on the summation of several low anity binding events
facilitated through high local protein concentrations after integrin receptor clustering.
3.3. Multiple mechanisms of FAK activation
As discussed above, both integrin and non-integrin stimuli can lead to increases in cellular
FAK tyrosine phosphorylation levels. However, it should be emphasized that since FAK
associates with and is a substrate for other PTKs, caution needs to be taken in making a direct
correlation between FAK tyrosine phosphorylation levels and FAK kinase activation. This
problem is most prevalent in serum-starved adherent ®broblasts where FAK can exist in a state
Fig. 4. b1 and b3 integrin cytoplasmic domain regions important for signaling events. Peptides derived from the
juxtamembrane portion of the b-cytoplasmic tails can bind to the FAK N-terminal domain in vitro. The integrity of
both C-terminal NXXY motifs, independently of their tyrosine phosphorylation, are important factors for integrin-
mediated FAK association and activation. Other short stretches of the b-integrin cytoplasmic tails can bind proteins
such as talin and a-actinin, and FAK interactions with these or other proteins may also facilitate the linkage
between the integrin cytoplasmic domains and FAK activation.
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at vinculin (Vin)-containing focal contact sites at the junction between the actin cytoskeleton and integrin receptors.
Though FAK is tyrosine phosphorylated under these conditions, it is not associated with Src-family PTKs and
exhibits only low in vitro kinase activity (probably due to an intramolecular steric interaction). B) Upon replating of
the cells on extracellular matrix proteins such as ®bronectin, FAK becomes activated either through conformational
changes or as a result of clustering mediated by integrin clustering. FAK autophosphorylation at Tyr-397 under
these conditions promotes the transient association of Src-family PTKs with FAK and the formation of a signaling
complex. C) Intracellular actin contractility events can promote further integrin receptor clustering and FAK
tyrosine phosphorylation. These events may promote the recruitment of additional proteins to focal contacts and
lead to the transphosphorylation of proteins such as paxillin (Pax). In all cases, FAK activation is dependent upon
the integrity of the actin cytoskeleton.
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conditions, Src-family PTKs are not signi®cantly associated with FAK and FAK exhibits only
low levels of in vitro kinase activity (Schlaepfer et al., 1998). This situation is depicted in a
model presented in Fig. 5A where FAK is localized to focal contacts, tyrosine phosphorylated,
but present in these integrin-containing structures in an inactive conformation. Since there are
precedents for the negative regulation of kinases through intramolecular steric interactions, one
speculative model is that FAK may be held in an inactive conformation though interactions
between the N- and C-terminal domains. Support for this model comes from studies whereby
either truncations (Schlaepfer and Hunter, 1996), insertions of alternate spliced sequences
(Burgaya et al., 1997), or chimeric membrane-spanning fusion proteins of FAK (Chan et al.,
1994) can generate FAK proteins with enhanced in vitro kinase activities.
How might integrin engagement with matrix proteins such as ®bronectin regulate FAK
PTK activity? By analogy to growth factor and cytokine receptors, ligand-induced integrin
clustering may also activate associated PTKs such as FAK (Fig. 5B). Integrin clustering or
integrin cytoplasmic domain conformation and alterations may promote the binding of the
N-terminal domain of FAK to the tail of a b integrin or another ligand, thus exposing
Tyr-397 (or pTyr-397). These FAK conformational changes could lead to the unmasking of
the FAK active site and/or allowing the catalytic domain to adopt an active conformation.
Integrin-dependent oligomerization of FAK would then permit transphosphorylation at Tyr-
397, and this in turn would recruit Src-family PTKs, resulting in the phosphorylation of
Tyr-576 and Tyr-577 in the FAK activation loop and full catalytic FAK activation.
Experimental conditions used to initiate this type of FAK activation are those which
involve the plating of adherent cell types onto matrix-coated dishes. FAK activation under
these conditions is transient (10 to 80 min) and occurs during the initial stages of rapid cell
spreading on the matrix-coated dishes. It is believed that this type of assay may mimic the
integrin-initiated signaling events that may occur at the leading edge of a migrating cell.
Again, it should be emphasized that it is dicult to distinguish enhanced FAK kinase
activity from FAK-associated Src-family PTK activity under these conditions. However,
recent studies have shown that the Src-speci®c PTK inhibitor, PP1, has minimal eects on
FAK in vitro kinase activity (Rodriguez-Fernandez and Rozengurt, 1998) and may be
useful in deciphering FAK-speci®c phosphorylation events.
Another point of emphasis should be placed upon the fact that transient integrin-stimulated
FAK activation depends upon the integrity of the actin cytoskeleton and is inhibited in the
presence of cytochalasin D. This connection to a cytoskeletal scaold for FAK activation is
most likely the key to understanding how FAK can become activated through p21 Rho-
mediated cell contractility events (Chrzanowska-Wodnicka and Burridge, 1996) and may also
represent a later stage (Fig. 5C) of replating-mediated FAK activation when actin stress ®bers
are formed and paxillin tyrosine phosphorylation is increased (Schlaepfer et al., 1998). This
type of conformational FAK activation would be dependent upon actin contractility combined
with cellular adhesion to a rigid substrate as in the case of a mature focal contact site. Further
integrin clustering under these circumstances would be driven by forces within the cell. It is
also possible that many of the non-integrin stimuli (Table 3) that aect FAK tyrosine
phosphorylation levels may engage FAK activation in this manner. In summary, it is likely
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regulate FAK activity and tyrosine phosphorylation events.
3.4. Integrin-mediated activation of Pyk2 and Src-family PTKs
Although initial reports suggested that Pyk2 was not activated by FN stimulation of rat
®broblasts (Sasaki et al., 1995), subsequent studies have shown that Pyk2 tyrosine
phosphorylation is enhanced by integrin stimulation of B cells (Astier et al., 1997a),
megakaryocytes (Li et al., 1996a), T lymphocytes (Ma et al., 1997), osteoclasts (Duong et al.,
1998) and after exogenous expression in chicken embryo ®broblasts (Schaller and Sasaki,
1997). In addition, Pyk2 expression is elevated in the FAK-null ®broblasts and the FN-
stimulated regulation of Pyk2 tyrosine phosphorylation in the FAK-null cells is very similar to
that of FAK in normal ®broblasts (Sieg et al., 1998). Is Pyk2 kinase activity, like FAK, also
regulated by integrin clustering? Again, direct analyses of Pyk2-associated in vitro kinase
activity are complicated by the integrin-stimulated association of Src-family PTKs with Pyk2
(Duong et al., 1998; Sieg et al., 1998). However, in Src-de®cient osteoclast-like cells, Pyk2 is
not detectably tyrosine phosphorylated after b3-mediated integrin stimulation (Duong et al.,
1998). In FAK-null ®broblasts, FN stimulation in the presence of the PP1 inhibitor of Src-
family PTKs or after overexpression of p50
csk (a negative regulator of Src-family PTKs),
resulted in dramatically lower levels of FN-stimulated Pyk2 tyrosine phosphorylation (Sieg et
al., 1998). As a comparison, inhibition of Src-family PTK activity in normal ®broblasts had
only minor eects on FN-stimulated increases in FAK tyrosine phosphorylation (Schlaepfer et
al., 1998; Sieg et al., 1998).
These results would suggest that elevated Pyk2 tyrosine phosphorylation may be downstream
of integrin-stimulated Src-family PTK activation events and this may be due to the inecient
localization of Pyk2 to sites of integrin clustering. This model is consistent with increased Pyk2
tyrosine phosphorylation being dependent upon Fyn PTK activity after T cell receptor
stimulation (Qian et al., 1997) and increased Pyk2 tyrosine phosphorylation being dependent
upon Syk PTK activity after FceRI receptor stimulation (Okazaki et al., 1997). Interestingly,
whereas the tyrosine phosphorylation of wild type Pyk2 expressed in CHO cells was not
regulated by FN plating, chimeric Pyk2 with the addition of FAK C-terminal domain
exhibited enhanced tyrosine phosphorylation and localization to focal contacts sites upon FN
stimulation of CHO cells (Zheng et al., 1998). These results reinforce the conclusion that FAK
or forced Pyk2 localization to sites of integrin receptor clustering is an important factor in
facilitating the direct activation of these PTKs.
Consistent with their importance for mediating integrin-stimulated signaling events in the
FAK
ÿ cells, Src-family PTKs can be independently activated with respect to Pyk2 and FAK
after FN stimulation of cells (Schlaepfer et al., 1998; Wary et al., 1998). In unstimulated
®broblasts, Src-family PTKs such as c-Src and Fyn are held in an inactive state through an
intramolecular association of the SH2 domain with a phosphorylated tyrosine residue in the C-
terminal tail of c-Src/Fyn (site of p50
csk phosphorylation) and by an interaction of the SH3
domain with the N-terminal lobe of the catalytic domain (Xu et al., 1997). Two possible initial
Src-family PTK activation mechanisms are dephosphorylation of the p50
csk phosphorylation
site or the binding of the SH2 and/or SH3 domains to alternative ligands.
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FN (Kaplan et al., 1995) and in cells de®cient for p50
csk, c-Src is highly activated and
constitutively localized to sites resembling focal contacts (Howell and Cooper, 1994).
Dephosphorylation of pTyr-527 in the C-terminal tail of c-Src is an early event in integrin-
stimulated c-Src activation (Kaplan et al., 1995) and in the FAK-null ®broblasts, p50
csk
overexpression inhibited FN-stimulated Src-family PTK activity (Sieg et al., 1998). Moreover,
overexpressed Csk localizes to focal contact sites and inhibits cell spreading (Bergman et al.,
1995). The identity of the integrin-stimulated PTP(s) that act on c-Src pTyr-527 are not known.
However, the transmembrane protein-tyrosine phosphatase, PTPa, has been shown to promote
the activation of both c-Src (den Hertog et al., 1993) and Fyn (Bhandari et al., 1998). In
addition, PTPa-null ®broblasts exhibit decreased Src PTK kinase activity and reduced levels of
FN-stimulated cell spreading and migration (J. Sap, personal communication).
When dephosphorylated in the C-terminal tail, the Src-family PTK SH2 domains would be
free to bind other ligands such as FAK. Overexpression of FAK enhances the level of FN-
stimulated Src-family PTK activity and this depends upon FAK Tyr-397 and FAK kinase
activity (Schlaepfer and Hunter, 1997). Conformational c-Src activation is likely to involve the
binding of the c-Src SH2 domain to FAK, via the FAK autophosphorylation site at pTyr-397.
Overexpression of Efs/Sin, a p130
Cas-related adaptor protein and Src-family PTK interacting
protein, also has been shown to enhance c-Src activity through both SH2 and SH3 domain-
mediated interactions (Alexandropoulos and Baltimore, 1996). Another proposed connection
between integrins and Src-family PTK activation events may involve the transmembrane
protein, caveolin-1 (Wary et al., 1998). In this model, caveolin-1 is proposed to form a speci®c
link between the transmembrane region of a integrins and Fyn (not c-Src) and upon a-integrin
clustering, Fyn is activated through unknown mechanisms. This model is controversial for the
fact that previous studies have shown that caveolin-1 association inhibits the activity of a
number of dierent signaling proteins, including Src-famiiy PTKs (Li et al., 1996b). In
summary, there may be multiple mechanisms linking integrins with Src-family PTK activation
events and in the next section, we will focus on how these PTK activation events are connected
to downstream signaling pathways.
4. Connections to downstream signaling pathways
4.1. FAK and Src-family PTKs link integrins to the activation of ERK2/mitogen-activated protein
(MAP) kinase
In 1991, it was ®rst observed that plating of ®broblasts onto FN-coated dishes rapidly
(within 10 min) stimulated the tyrosine phosphorylation of a 0120 kDa protein (Guan et al.,
1991) and this protein turned out to be FAK. In 1994, a number of labs reported that FN-
stimulation of ®broblasts promoted signaling to and the activation of the ERK2/MAP kinase
cascade (for a review see Schwartz et al., 1995). This observation now has been extended to a
number of dierent cell types, however the role of FAK in these signaling events endures as a
debated issue (for a review see Aplin et al., 1998). One of the ®rst issues raised was that
antibody-mediated clustering a6 integrins led to increases in FAK tyrosine phosphorylation
D.D. Schlaepfer et al. /Progress in Biophysics & Molecular Biology 71 (1999) 435±478 455without detectable ERK2 activation and that a cytoplasmic tail-less a1 integrin chimera could
promote ERK2 activation in the absence of detectable FAK tyrosine phosphorylation events
(Wary et al., 1996). It has been subsequently shown that a6 integrin stimulation can indeed
facilitate ERK2 activation (Wei et al., 1998) and as will be discussed below, results obtained
from FAK knockout ®broblasts show that there is more than one pathway leading to ERK2
activation and that FAK per se is not essential for FN-stimulated signaling to ERK2.
A second debatable issue raised is the time course of FN-stimulated FAK and ERK2
activation in ®broblasts allowed to spread on FN-coated dishes. One study using NIH3T3
®broblasts showed that maximal FN-stimulated ERK2 activation occurred within 10 min
which preceded cell spreading and detectable increases in FAK tyrosine phosphorylation (Lin
et al., 1997). However, other studies using human foreskin ®broblasts and bead clustering
experiments with the a5b1 FN receptor, showed that FAK was rapidly recruited to aggregated
integrin receptor complexes prior to the accumulation of other signaling proteins such as the
Src-family PTKs (Miyamoto et al., 1995a). In this latter study, maximal ERK2 activation was
observed 030 min after stimulation of cells with FN-coated beads. Also, in a number of other
cell lines stimulated by the replating method, increased FAK tyrosine phosphorylation
occurred in parallel with FN-stimulated ERK2 activation (maximal between 20 and 40 min)
and was correlated with the initiation of cell spreading (Zhu and Assoian, 1995; Schlaepfer et
al., 1998; Short et al., 1998).
Given that stimulated tyrosine kinase activation events are important for integrin receptor
signal generation, there is no disagreement as to whether initial integrin receptor clustering can
generate signals to targets such as ERK2. The question is at what point does maximal integrin
signaling occur, is FAK involved, and does integrin-stimulated ERK2 activation aect a
particular biological response? Clearly these events may dier between cell types, however it
has been shown that ®broblasts allowed to spread on FN-coated plates can generate signals
leading to enhanced FAK tyrosine phosphorylation and extended ERK2 activation for up to
1±2 h (Zhu and Assoian, 1995; Schlaepfer et al., 1998). Although these ERK2 signals on their
own are not sucient to promote DNA synthesis (Zhu and Assoian, 1995), it has been shown
that cell spreading on and remodeling of a FN matrix enhances cell growth (Sechler and
Schwarzbauer, 1998; Sottile et al., 1998). Antibody-mediated clustering of integrins (Wary et
al., 1996) or cell binding to fragments of FN which do not stimulate spreading, generate
transient signals to ERK2 (maximal at 10 min) (Lin et al., 1997). This transient level of
integrin activation is not sucient to promote cell survival signals (Chen et al., 1997; Sottile et
al., 1998). In adherent cell types, it is likely that there is a greater and extended level of
integrin receptor activation in a spreading cell pulling and moving on the FN matrix
substratum as opposed to a rounded cell with a small patch of membrane containing clustered
integrin receptors.
It should be emphasized that one distinguishing feature between integrin receptor- and
growth factor receptor-stimulated ERK2 activation events is that the integrin signals are
dependent upon the integrity of the actin cytoskeleton whereas growth factor receptor PTKs
can signal to ERK2 in the presence of cytochalasin D (Miyamoto et al., 1995a; Schlaepfer et
al., 1998; Short et al., 1998). Integrin-stimulated ERK2 activation and cell spreading is
connected to the coordinated engagement and rearrangement of the cellular actin cytoskeleton.
Signaling models which propose that the transmembrane integrin receptor domains are
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address the critical role of the cytoskeleton in integrin-stimulated ERK2 activation events
(Wary et al., 1998). In contrast, it is more likely that multiple inputs from the activation of
tyrosine kinases, small GTP binding proteins (Renshaw et al., 1996; Clark et al., 1998), serine-
threonine kinases such as protein kinase C (Schlaepfer et al., 1998), and lipid kinases such as
phosphatidylinositol 3-kinase (King et al., 1997) act in a coordinated manner to regulate the
extent and duration of integrin-stimulated ERK2 activation.
Our focus will be on the multiple connections linking the FAK and Src-family PTKs with
the activation of ERK2. Maximal FAK kinase activity, ERK2 activation, and cell spreading
occurred in the 20 to 60 min period following initial FN stimulation of mouse ®broblasts
(Schlaepfer et al., 1998). As discussed in the preceding sections, maximal FN-stimulated FAK
kinase activity is correlated with the binding of Src-family PTKs to FAK. Both activated FAK
(Schlaepfer et al., 1998; Sharma, 1998) and c-Src (Kaplan et al., 1995) selectively partition to
the 1% triton-insoluble fraction of cell lysates after FN stimulation of cells. This may explain
why other studies have failed to visualize initial FAK tyrosine phosphorylation events after
integrin stimulation of cells (Wary et al., 1996; Lin et al., 1997). Notably, the phosphorylation
of FAK residues in addition to FAK Tyr-397, were enhanced in the Triton-insoluble cell
fraction after FN stimulation (Schlaepfer et al., 1998) and one of these was the Grb2 binding
site on FAK at Tyr-925. Grb2 binding to FAK and its association with the SOS GDP-GTP
exchange factor for Ras is a direct link to the activation of the ERK2/MAP kinase pathway
(Schlaepfer et al., 1994; Chen et al., 1998).
As shown in the signaling model (Fig. 6), Src-family PTK binding to FAK at FAK Tyr-397
after integrin-stimulation is required for the subsequent Src-mediated phosphorylation of FAK
Tyr-925 (Schlaepfer and Hunter, 1996). However, Grb2 binding to FAK is not essential to
promote integrin signaling to ERK2, since overexpression of either wild type or the Grb2
binding site mutant (Phe-925) of FAK can both enhance FN-stimulated activation of ERK2
(Schlaepfer and Hunter, 1997). In contrast, overexpression of the c-Src binding site mutant
(Phe-397) of FAK inhibits FN-stimulated signaling to ERK2 in human 293T cells (Schlaepfer
and Hunter, 1997). In addition, Phe-397 FAK expression inhibits integrin-mediated shear
stress-stimulated signaling to the JNK/MAP kinase in bovine aortic endothelial cells (Li et al.,
1997a,b) implying that FAK interactions with Src family PTKs are important for the initiation
of signaling events. However, mutation of the FAK Tyr-397 also disrupts the binding of other
SH2 domain-containing proteins that are involved in signaling events. For instance, the
Phe-397 FAK mutation disrupts the binding of the p85 subunit of PI 3-kinase (Chen et al.,
1996), and inhibition of PI 3-kinase activity reduces the level of integrin-stimulated signaling to
ERK2 in COS-7 ®broblasts (King et al., 1997). In addition, the Shc adaptor protein SH2
domain also binds to the Tyr-397 site in FAK (Schlaepfer and Hunter, 1997; Schlaepfer et al.,
1998) (see Fig. 6).
It is the tyrosine phosphorylation of the Shc adaptor protein which is a major integrin-
stimulated signaling pathway to ERK2. Phosphorylation of Shc at Tyr-239 or Tyr-317 creates
multiple Grb2 SH2 domain binding sites on Shc (van der Geer et al., 1996). FAK
overexpression enhances Shc tyrosine phosphorylation and Grb2 binding to Shc after FN
stimulation of 293T cells (Schlaepfer and Hunter, 1997). However, although FAK can bind to
and directly phosphorylate Shc at Tyr-317, thereby promoting Grb2 binding and low-level
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also requires the activation of Src-family PTKs (Schlaepfer et al., 1997). In Src-de®cient
®broblasts, FN-stimulated Shc tyrosine phosphorylation and ERK2 activity are reduced
compared to the same cells re-expressing mouse c-Src (Schlaepfer et al., 1997) and compared to
normal ®broblasts (D. Schlaepfer, unpublished results). More dramatic reductions in FN-
stimulated Shc tyrosine phosphorylation and ERK2 activation have been reported to occur in
Fyn-de®cient ®broblasts (Wary et al., 1998).
Signi®cantly, it has been shown that Phe-317 Shc overexpression can block FN-stimulated
and Fyn-mediated ERK2 activation in ®broblasts (Wary et al., 1998). In contrast, c-Src can
phosphorylate both wild type (WT) and Phe-317 Shc to promote Grb2 binding (Schlaepfer et
Fig. 6. Integrin-stimulated signaling events involving FAK. Integrin receptor engagement with ligands such as
®bronectin can stimulate FAK autophosphorylation at Tyr-397 which creates a c-Src SH2 domain binding motif.
The recruitment and subsequent activation of Src-family PTKs is an important event in FAK-mediated signaling
and this FAK/Src complex is linked to multiple signaling pathways. Src-mediated phosphorylation of FAK at Tyr-
925 creates a binding site for the SH2 domain of the Grb2 adaptor protein. Integrin activation of both FAK and
Src-family PTKs can promote Shc tyrosine phosphorylation and Grb2 binding to Shc at Tyr-317. Grb2 binding to
these signaling complexes can potentiate the translocation of the GDP/GTP exchange protein SOS to the plasma
membrane leading to enhanced GTP exchange on Ras. The activation of the ERK/MAP kinase cascade is one
target for the actions of GTP-bound Ras. Integrin-stimulated Ras may also activate PI 30-kinase which may provide
cell survival signals through the activation of targets such as the Akt serine-threonine kinase. PI 30-kinase may also
facilitate the coupling of Ras to the Raf-1 kinase leading to the enhanced activation of ERK/MAP kinase pathway.
Src-family association with FAK at sites of integrin clustering can also potentiate the association and tyrosine
phosphorylation of p130
Cas. Crk and Nck adaptor protein binding to tyrosine-phosphorylated p130
Cas may lead to
enhanced cell migration through the activation of pathways potentially involving the Rac GTPase or the JNK MAP
kinase cascade. FAK may also link integrin activation to the regulation of cell cycle progression by in¯uencing the
levels of cyclin D1 and p21 inhibitor expression.
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phosphorylated after FN-stimulation in human 293T cells and its expression did not block
ERK2 activation in these cells (Schlaepfer et al., 1998). This contrasts with studies which have
detected only the FN-stimulated tyrosine phosphorylation of WT and not Phe-317 Shc in 293T
cells (Wary et al., 1998). Since Src-family PTKs such as c-Src and Fyn have similar substrate
speci®cities (Songyang et al., 1995), it is very dicult to reconcile these observations. Although
these ®ndings call in question whether one particular Grb2 binding site on Shc is essential for
FN-stimulated signaling to ERK2, overexpression of SH3 domain-inactivated mutant of Grb2
that is unable to bind targets such as the SOS GDP-GTP exchange protein for Ras, inhibited
both FN-stimulated and FAK-enhanced ERK2 activation (Schlaepfer et al., 1998). These latter
results are consistent with a model whereby multiple Grb2-dependent interactions with FAK,
Shc, and perhaps other yet-to-be-determined phosphorylated targets represent parallel signaling
pathways upstream of Ras that cooperate to promote maximal FN-stimulated ERK2
activation (Fig. 6). One of these other FN-stimulated ERK2 signaling pathways may involve
the protein-tyrosine phosphatase SHP-2 which associates with Grb2 and the tyrosine-
phosphorylated membrane glycoprotein SHPS-1 (Tsuda et al., 1998).
4.2. Fibronectin-stimulated signaling to ERK2 in the absence of FAK
Although the involvement of FAK-related PTKs in matrix-mediated ERK2 activation events
may be evolutionarily conserved down to trophozoites (Perez et al., 1996), accumulating
evidence suggests that FAK is not essential for FN-stimulated ERK2 activation events. This
was ®rst observed upon overexpression of dominant-negative constructs such as FRNK which
can reduce FAK tyrosine phosphorylation levels (Gilmore and Romer, 1996; Richardson et al.,
1997a) but which do not block FN-stimulated ERK2 activation events (Lin et al., 1997; Wary
et al., 1998). Although interpretations of results using dominant-negative constructs can be
problematic, FAK-independent integrin-stimulated signaling events are likely to occur in
hematopoietic cells (Gao et al., 1997; Hunter and Shimizu, 1997; Meng and Lowell, 1998)
where FAK protein expression is quite low. Importantly, FAK-de®cient (FAK
ÿ) ®broblasts
have been established and not surprisingly, the expression of Pyk2 is elevated in the FAK
ÿ
cells (Ueki et al., 1998). However unlike FAK, Pyk2 exhibits a perinuclear distribution and
does not strongly colocalize with the elevated number of focal contact sites of the FAK
ÿ cells
(Sieg et al., 1998). Signi®cantly, increased Pyk2 pTyr levels paralleled the time course of Grb2
binding to Shc and the activation of ERK2 after FN stimulation of the FAK
ÿ cells (Sieg et
al., 1998). Interestingly, Pyk2 autophosphorylation activity was not enhanced by FN
stimulation of the FAK
ÿ cells, instead, FN stimulation promoted the association of Pyk2 with
active Src-family PTKs (Sieg et al., 1998). Overexpression of both wild type (WT) and kinase-
inactive (Ala-457) but not the autophosphorylation site mutant (Phe-402) of Pyk2 enhanced
endogenous FN-stimulated c-Src in vitro kinase activity in the FAK
ÿ cells, but only WT Pyk2
overexpression enhanced the FN-stimulated activation of cotransfected ERK2 (Sieg et al.,
1998).
These results support the hypothesis that in the absence of FAK, Pyk2 functions in the FN-
stimulated signaling events leading to ERK2 activation (see Fig. 9). The Pyk2 overexpression
results suggest that an SH2-mediated interaction of Src-family PTKs with Pyk2 at Tyr-402 may
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ÿ
cells. In addition, these results support the conclusion that Pyk2 kinase activity and the
phosphorylation of Pyk2 Tyr-402 are important components of the FN-stimulated signaling
cascade to ERK2 in the FAK
ÿ cells. The fact that the FN-stimulated regulation of Pyk2
tyrosine phosphorylation in the FAK
ÿ cells (but not kinase activity) is very similar to FAK in
normal ®broblasts suggests that increased Pyk2 expression and tyrosine phosphorylation in the
FAK
ÿ cells is a compensatory event for the loss of FAK. Interestingly, cytochalasin D
treatment of the FAK
ÿ cells inhibits both increased Pyk2 tyrosine phosphorylation and ERK2
activation (D. Schlaepfer, unpublished results) whereas cytochalasin D has been shown to
stimulate Src-family PTK activity (Lock et al., 1998). This would suggest that Src-family PTKs
cannot function singularly to promote FN-stimulated ERK2 activation. Instead, it is more
likely that phosphorylated Pyk2 or the actin cytoskeleton are both functioning in combination
with Src-family PTKs to facilitate integrin signaling to ERK2.
4.3. Negative regulators of integrin signaling events
In addition to the elevated expression of Pyk2 in the FAK
ÿ cells, the level of FN-stimulated
Src-family PTK activity was higher in the FAK
ÿ compared to normal FAK
+ ®broblasts
(Sieg et al., 1998). This was due in part to the elevated dephosphorylation of the murine c-Src
Tyr-529 regulatory residue which is the site of p50
csk phosphorylation. Signi®cantly,
overexpression of p50
csk inhibited FN-stimulated Src-family PTK activity, Pyk2 tyrosine
phosphorylation, Grb2 binding to Shc, and ERK2 activation in the FAK
ÿ cells (Sieg et al.,
1998). These results suggest that the integrin-stimulated increase in Pyk2 tyrosine
phosphorylation in the FAK
ÿ cells is indirect and occurred through the activation of
Src-family PTKs. However, the molecular mechanism connecting the FN receptor integrins
with c-Src and Fyn PTK activation in the FAK
ÿ cells is at present not known.
In normal ®broblasts, p50
csk overexpression did not block FN-stimulated increased FAK
tyrosine phosphorylation and p50
csk only partially reduced the amount of FN-stimulated Grb2
binding to Shc and signaling to ERK2 (Sieg et al., 1998). These results are consistent with the
direct activation of FAK after integrin stimulation of cells and also support the hypothesis for
the existence of Src-independent integrin-stimulated signaling pathways to ERK2 in normal
®broblasts (Schlaepfer et al., 1998). Therefore, the molecular mechanisms of integrin signaling
to ERK2 should not be envisioned as a linear pathway (Wary et al., 1998), but instead these
events can be considered as a networked interaction of a number of dierent signaling
proteins. In this network, the positive elements (PTKs) are balanced by the activity of the
negative regulators, p50
csk and protein-tyrosine phosphatases (PTPs). One such PTP that acts
as a negative regulator is PTP1B which binds to p130
Cas (Liu et al., 1998). Overexpression of
PTP1B resulted in lower levels of FN-stimulated FAK and p130
Cas tyrosine phosphorylation
and PTP1B inhibited FN but not growth factor-stimulated ERK2 activation (Liu et al., 1998).
Other potential negative regulators of FN-stimulated signaling events include the FAK-
associated PTP, PTEN (Tamura et al., 1998) and the p130
Cas and paxillin-associated PTP,
PTP-PEST (Garton et al., 1997; Shen et al., 1998). Interestingly, overexpression of a
catalytically inactive form of SHP-2 inhibited FN-stimulated ERK2 activation implying that
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(Tsuda et al., 1998).
4.4. FAK and Pyk2 signals through p130
Cas tyrosine phosphorylation
In contrast to the pathways leading to FN-stimulated ERK2 activation, less is known about
what signals are generated by phosphorylation of the p130
Cas adaptor protein. In a number of
dierent cell types, p130
Cas or related adaptor proteins (Ishino et al., 1997; Law et al., 1998;
Ohashi et al., 1998) have been shown to be substrates for either FAK (Tachibana et al., 1997),
Pyk2 (Manie et al., 1997b), Src-family (Manie et al., 1997a; Sakai et al., 1997), or activated
Abl (Law et al., 1996; Salgia et al., 1996b) PTKs. These tyrosine phosphorylation events have
been shown to promote the SH2-dependent binding of either the Crk (Vuori et al., 1996), Crkl
(de Jong et al., 1997) or Nck (Schlaepfer et al., 1997) SH3/SH2 domain-containing adaptor
proteins to p130
Cas (Fig. 6). Although both Crk and Nck have been shown to bind to the SOS
GDP-GTP exchange factor that activates Ras and the ERK2/MAP kinase pathway, integrin-
stimulated p130
Cas tyrosine phosphorylation may not be tightly linked to ERK2 activation. In
Src-de®cient ®broblasts, where p130
Cas is not appreciably tyrosine phosphorylated after
integrin stimulation, stable expression of a kinase-inactive Src fragment (Src 1±298) in the Src-
de®cient cell background lead to strong FAK-mediated p130
Cas tyrosine phosphorylation, Nck
binding to p130
Cas, but relatively small increases in integrin-stimulated ERK2 activation
compared to Src
ÿ cells (Schlaepfer et al., 1997).
Recent results have suggested that the Nck adaptor protein may connect to the JNK/MAP
kinase cascade through interactions with SH3 domain-associated protein-serine/threonine
kinases such as PAK or NIK (Bokoch et al., 1996; Su et al., 1997). In addition, it has been
shown that Crk can connect to the JNK/MAP kinase cascade through an interaction with the
C3G guanine nucleotide exchange protein (Tanaka et al., 1997). Thus, the ability of integrins
to facilitate JNK activation (Miyamoto et al., 1995b; Mainiero et al., 1997) may be mediated
in part by either Nck or Crk adaptor binding to tyrosine phosphorylated p130
Cas.
4.5. Targets of integrin-stimulated MAP kinase activation events
The role of JNK/MAP kinase activation downstream of integrins is not known. For the ERK/
MAP kinase pathway, signals can feed back to decrease integrin receptor ligand binding anity
and this may provide a negative feedback loop in the regulation of integrin-stimulated signaling
events (Hughes et al., 1997). In addition, integrin-activated ERK2 can phosphorylate and
regulate the activity of cytoplasmic proteins such as phospholipase A2 (Clark and Hynes, 1996)
and myosin light chain kinase (Klemke et al., 1997). Since FN-stimulation can promote the
activation and nuclear translocation of ERK2 (Chen et al., 1994), ERK or JNK could promote
transcription factor phosphorylation events and account for some of the known gene induction
responses to integrin signals (Huhtala et al., 1995; Wary et al., 1996; Mainiero et al., 1997).
It has also been proposed that integrin-stimulated ERK2 activation is important for the cell
adhesion-dependent regulation of cell cycle progression (Wary et al., 1996; Wary et al., 1998).
One target for ERK2 activity is the regulation of cyclin-dependent kinase activity (for a review
see Bottazzi and Assoian, 1997). Consistent with a role of FAK in the regulation of integrin
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progression at the G1 phase through the inhibition of cyclin D1 expression and by promoting
the increased expression of the p21 inhibitor of cyclin-dependent kinases (Zhao et al., 1998).
This FAK mutant was not localized to focal contacts and its inhibitory activity was dependent
on the integrity of the FAK Tyr-397 phosphorylation site. It has been hypothesized that this
inhibitory FAK mutant competes with endogenous FAK in cells for the binding of signaling
molecules such as the Src-family PTKs (Zhao et al., 1998). Other studies also support a role
for FAK in the regulation of cell cycle progression as the treatment of cells with fragments of
FN suppressed FAK tyrosine phosphorylation events and resulted in the delay of the G1 to S
transition (Sechler and Schwarzbauer, 1998).
4.6. Role for FAK and p130
Cas in Src-mediated cell transformation events
The integrin stimulated increases in FAK and p130
Cas tyrosine phosphorylation events occur
transiently in normal cells and are subject to many regulatory factors. In Src-transformed cells,
both FAK and p130
Cas tyrosine phosphorylation levels are signi®cantly elevated even in cells
deprived of integrin-generated adhesion signals. Moreover, FAK was originally identi®ed using
a monoclonal antibody developed against a v-Src-associated protein (Kanner et al., 1990), and
p130
Cas was originally characterized as a v-Crk-associated protein (Sakai et al., 1994). In v-Src
transformed cells the Grb2 binding site on FAK at Tyr-925 is constitutively phosphorylated
and the SOS GDP-GTP exchange protein for Ras can be detected in association with FAK
isolated from v-Src transformed cells (Schlaepfer et al., 1994). Fibroblasts isolated from the
p130
Cas knockout mouse and transfected with an activated Src allele show a reduced ability to
grow in soft agar compared to p130
Cas re-expressing cells in combination with activated Src
(Honda et al., 1998). In addition, the p130
Cas-de®cient cells show resistance to Src-induced
morphological changes. These ®ndings support the hypothesis that the same FAK, Src, and
p130
Cas signaling pathways which are transiently activated by integrin stimulation in normal
cells may push cells toward a transformed phenotype when constitutively activated in Src-
transformed cells (for a review see Brugge, 1998).
4.7. FAK signals important for cell survival
To grow in culture, many normal cells require both adhesion to ECM proteins and stimulation
by serum or growth factors. One mechanism by which integrin receptors enhance cell survival is
by counteracting signals for programmed cell death. When deprived of contact with ECM
proteins, epithelial and endothelial cells rapidly lose viability and undergo `anoikis' or apoptosis
(for a review see Meredith and Schwartz, 1997). Integrin stimulation of both the Rho (Schwartz
et al., 1996) and Ras/PI 3-kinase (Khwaja et al., 1997) signaling pathways can prevent this
suspension-mediated cell death. In addition, it has been shown that endothelial cell spreading but
not simple attachment to FN generates important cell survival signals (Chen et al., 1997). As we
discussed in this review, FAK is activated during the process of FN-stimulated cell spreading in
many cell types. Antisense (Xu et al., 1996) or antibody-mediated (Hungerford et al., 1996)
inhibition of FAK has been shown to result in increased apoptosis of cultured cells.
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while also promoting anchorage-independent cell growth in soft agar (Frisch et al., 1996).
Signi®cantly, both FAK kinase activity and the Tyr-397 autophosphorylation site were
required for FAK-mediated survival signals, which implicates that signaling may occur through
Src-family PTKs or other SH2-containing adaptor proteins such as the p85 subunit of PI 3-
kinase (Chen et al., 1996). In addition, it has been shown that integrin and FAK-mediated
survival signals suppress a p53-regulated apoptotic pathway (Ilic et al., 1998). In the absence of
p53 or in the presence of dominant-negative p53 constructs, cells can survive even if they lack
integrin-generated survival signals or even if they lack FAK (Ilic et al., 1998). A model
emerging from these results is that p53 monitors survival signals from integrins/FAK in
anchorage dependent cells and that during the processes of cell transformation, mutations in
the p53 tumor suppressor gene will allow for anchorage-independent cell survival.
4.8. Early caspase cleavage of FAK during apoptosis
Since FAK has been shown to be involved in the processes of promoting cell survival, it is not
surprising that cell stimuli such as Fas ligand and Apo-2L (Wen et al., 1997), UV irradiation
(Widmann et al., 1998), or growth factor deprivation (Levkau et al., 1998) can promote the
cleavage and degradation of FAK during the early stages of cell apoptosis. Interestingly, during
c-Myc-induced apoptotic events, proteolysis of FAK is suppressed by FN stimulation of cells
suggesting that FAK activation can prevent its own degradation (Crouch et al., 1996). The
cleavage of FAK coincides with the loss of FAK from focal contacts, cell rounding, and the
redistribution of FAK to characteristic apoptotic membrane protrusions (Levkau et al., 1998). In
human endothelial cells, FAK is cleaved into two fragments of 090 and 035 kDa. The site of
FAK cleavage was mapped to Asp-772 in the C-terminal domain of FAK (Gervais et al., 1998)
and this site (Asp-Gin-Thr-Asp
*) is recognized by the caspase-3 protease in vitro (Fig. 7). The
signi®cance of FAK cleavage at Asp-772 is that the remaining 90 kDa fragment of FAK
containing the kinase domain would not contain the residues important for focal contact
localization in cells. Overexpression of the predicted caspase-generated C-terminal FAK fragment
(773±1053) promoted the dephosphorylation of endogenous FAK (Gervais et al., 1998) similar to
the observed eects of FRNK overexpression on FAK pTyr levels in chicken embryo ®broblasts
(Richardson and Parsons, 1996).
Although this Asp-772 caspase-3 cleavage site is conserved in human, chicken, and frog
FAK cDNA sequences, it is not conserved in murine or rat FAK (Fig. 7). In NIH3T3 murine
®broblasts, staurosporine treatment led to the generation of a075 kDa FAK fragment and the
caspase site of FAK cleavage was mapped to Asp-704 (Gervais et al., 1998). It is of interest
that these two sites of caspase cleavage lie on either side of the ®rst proline-rich domain in
FAK which is the site of SH3 domain protein binding interactions. Not only does caspase
cleavage of FAK separate the kinase domain from the C-terminal focal adhesion targeting
sequences, these C-terminal FAK fragments may act to advance the pace of the cell death
process. Exogenous expression of the FAK FAT domain (residues 841±1053) into primary
®broblasts promotes apoptosis in a p53-dependent manner which is suppressible by Bcl2 but
not CrmA (Ilic et al., 1998). This fragment of FAK has been termed the `killer' FAT domain
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localization to focal contacts and the longer FRNK fragment of FAK (residues 691±1053)
does not promote cell death (Ilic et al., 1998). These results would indicate that FAK residues
such as the ®rst proline-rich domain (712±718) may prevent the killer FAT-mediated cell death
through the balanced activation of some survival pathway. Interestingly, it has been noted that
murine NIH3T3 ®broblasts are relatively resistant to apoptosis (Frisch et al., 1996) and
caspase cleavage of murine FAK at Asp-704 would not generate the killer FAT fragment of
FAK. However, it remains to be determined whether exogenous expression of the FAK Asp-
772 cleavage fragment will push NIH3T3 cells faster toward cell death or whether the larger
Asp-704 fragment will delay these events.
Fig. 7. Caspase cleavage of FAK. During the initial events of cell apoptosis, caspase-3 has been shown to cleave
FAK at Asp-772 and Asp-704 of human and mouse FAK, respectively. The sequences recognized by caspase-3 are
conserved over a broad range of species. Cleavage at these sites leads to the generation of a large N-terminal
fragment comprising the kinase domain (090 kDa for human FAK, 075 kDa in the case of mouse FAK) and a
smaller C-terminal fragment (035 kDa or 50 kDa, respectively) that contains the focal adhesion targeting sequence
and one or both proline-rich SH3-domain binding sites. Exogenous expression of the Asp-772 C-terminal FAK
fragment can promote cell apoptosis and has been termed the `killer' FAT fragment. This activity is dependent upon
the integrity of the FAT domain.
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5.1. FAK functions to enhance cell spreading and migration
Cell migration relies upon forces generated by the cell and the regulation of the adhesive
strength between the integrin and cell substratum interface (for reviews see Lauenburger and
Horwitz, 1996; Sheetz et al., 1998). In contrast to recent progress in the understanding of
intracellular signaling pathways involved in cell proliferation and survival, less is known about
potential signal transduction pathways leading to cell migration. The mechanisms regulating
integrin-stimulated cell migration are very complex and the activation of tyrosine kinases play
an important role in these events (Klemke et al., 1994; Romer et al., 1994). Emerging evidence
supports the role of both FAK and Src-family PTKs in these processes. Src-de®cient
®broblasts exhibit slower kinetics of FN-initiated cell spreading (Kaplan et al., 1995) and
FAK-de®cient ®broblasts exhibit an enhanced number of cell substratum contacts and reduced
rates of cell migration (Ilic et al., 1995b). Interestingly, vinculin knockout ®broblasts exhibit no
apparent defects in focal adhesion formation, however these cells displayed elevated levels of
FN-stimulated FAK tyrosine phosphorylation and increased rates of cell migration (Xu et al.,
1998). In the epidermal-dermal junction of repairing burn wounds, FAK expression is elevated
as detected by immunohistochemical staining (Gates et al., 1994). These sites correspond to the
basal edge of only those keratinocytes that are actively migrating and rapidly proliferating in
repairing burn wounds.
In cultured cells, FAK overexpression can increase FN-stimulated cell motility and this
activity depends upon the integrity of the FAK Tyr-397 autophosphorylation site (Cary et al.,
1996). In addition, overexpression of FRNK can inhibit endogenous FAK tyrosine
phosphorylation, cell spreading on FN-coated dishes (Richardson et al., 1997a) and inhibit
endothelial cell migration in cultured cell wound healing assays (Gilmore and Romer, 1996).
Signi®cantly, the FRNK-mediated inhibitory eects can be rescued by coexpression of active
Src-family PTKs in chicken embryo ®broblasts (Richardson et al., 1997a). These results would
suggest that FAK-recruitment of Src-family PTK to sites of integrin clustering is an important
component of FAK-mediated cell migration events. This model is supported by results showing
that FAK-mediated recruitment of Src to focal adhesions controls the turnover of these
structures during cell migration (Fincham and Frame, 1998). Although there is much evidence
in support of the importance of a FAK/Src complex in promoting cell migration, to date there
is no consensus on what downstream signaling events from this complex are required for the
initiation of cell migration. In the next section, we will review a number of dierent proposed
models of FAK/Src function in promoting cell migration events.
5.2. FAK/Src complex connections to increased cell motility
One hypothesis is that FAK-mediated Src recruitment to focal contacts promotes yet-to-be-
identi®ed tyrosine phosphorylation events that led to the degradation of FAK and the
remodeling of cell substratum contact sites (Fincham and Frame, 1998). This model is based
upon the assumption that FAK is involved in the formation of focal contact structures and
that its degradation allows for the turnover of these structures. Other work has focused on the
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(Richardson et al., 1997a). Since paxillin has been shown to associate with PTP-PEST (Shen et
al., 1998), it is possible that this connection may somehow regulate the cycles of
phosphorylation and dephosphorylation important for the cell migration process. Another
potential component linking the FAK/Src complex to cell migration is the activation of the
ERK2/MAP kinase cascade. It has been shown that blockage of the ERK2 pathway at the
level of the MEK kinase inhibits FN-stimulated Rat-1 ®broblast migration (Anand-Apte et al.,
1997). In other cells, ERK2 inhibition also reduces cell motility and it has been shown that
direct ERK2 phosphorylation of myosin light chain kinase promotes the enhanced
phosphorylation of myosin light chains, an initial event necessary for contractility-mediated cell
migration (Klemke et al., 1997). In agreement with the importance of ERK2 in cell migration,
it has been shown that FAK and Ras were required for ERK2 activation and matrix
metalloproteinase secretion in the processes of FN-stimulated ovarian cancer cell migration
(Shibata et al., 1998). The increased secretion and activity of metalloproteinases is another
point at which the adhesive strength between the integrins and cell substratum interface could
be modulated to promote increased cell migration. These models connecting FAK and ERK2
to either the regulation of cytoskeletal architecture or gene expression events ®t with the
required role of Ras activity for endothelial cell migration (Fox et al., 1994).
However not all migratory signals may go through the Ras-ERK2 cascade. Recent evidence
suggests that Src-associated signaling events may be able to promote epithelial cell scattering
through the activation of signaling pathways distinct from those activated by Ras (Boyer et al.,
1997). Namely, it has been proposed that Src can promote epithelial cell dispersion in the
absence of gene expression through phosphorylation events that aect the organization of the
cortical cytoskeleton (Boyer et al., 1997). Although, it is quite possible that mechanistic
dierences exist between epithelial cell scattering and integrin-stimulated cell migration of
®broblasts or endothelial cells, the FAK or Src-mediated phosphorylation of a target such as
p130
Cas may connect to a novel non-ERK2-dependent signaling pathway involved in
promoting cell migration. This model is supported by the fact that the ®rst proline-rich domain
of FAK (binding site of p130
Cas) is important for FAK overexpression-mediated CHO cell
migration and exogenous expression of the SH3 domain of p130
Cas can inhibit FAK-mediated
cell motility (Cary et al., 1998). Signi®cantly, Crk adaptor protein binding to phosphorylated
p130
Cas has been shown to promote cell migration in a Rac-dependent and Ras-independent
manner (Klemke et al., 1998). Although not completely de®ned, downstream components of
this Rac-mediated migration pathway may involve PI-3-kinase (Keely et al., 1997; Shaw et al.,
1997) and/or cytoskeletal-associated targets such as gelsolin (Azuma et al., 1998; Chellaiah et
al., 1998).
5.3. Phenotype of the FAK knockout
The strongest evidence linking FAK with the cell migration machinery comes from the
analyses of the FAK-de®cient ®broblasts. Null mutations in either the murine FN (George et
al., 1993) or FAK (Ilic et al., 1995a) genes lead to similar embryonic lethal phenotypes as a
result of defective developmental gastrulation events. As shown in Fig. 8, FAK
ÿ ®broblasts
exhibit a rounded morphology and an elevated number of small vinculin-positive sites of cell-
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+) ®broblasts. Since the
FAK
ÿ ®broblasts exhibit reduced rates of cell motility (Ilic et al., 1995a), it is likely that
FAK-mediated tyrosine phosphorylation events are involved in the turnover of these contact
sites during the initial stages of cell spreading and migration. In addition to the FAK knockout
results, experiments with chimeric mice made from b1 integrin-null stem cells have shown that
b1-initiated signals in the context of a developing mouse are also important for cell migration
events (Hirsch et al., 1996). One interpretation of these combined results is that FN may
stimulate cell migration through b1 integrin-mediated signaling events involving FAK.
Similar to models of FAK function in signal transduction pathways, it is tempting to link
increased FAK tyrosine phosphorylation with increased cell migration. Indeed, studies have
shown that the PTEN tyrosine phosphatase is a negative regulator of FAK tyrosine
phosphorylation and cell migration (Tamura et al., 1998). However, ®broblasts containing a N-
terminally truncated form of the SHP2 tyrosine phosphatase (Yu et al., 1998) or ®broblasts
de®cient in the PTP-PEST (M. Tremblay, personal communication) contain elevated tyrosine
phosphorylation levels of FAK, paxillin, and p130
Cas and these ®broblasts also exhibit
Fig. 8. Focal contact formation in FAK
+ and FAK
ÿ ®broblasts. FAK-expressing (FAK
+) and FAK-de®cient
(FAK
ÿ) primary mouse embryo ®broblasts were allowed to adhere to a FN-coated surface for 60 minutes. Whereas
the FAK
+ cells spread over the surface and acquired an elongated phenotype, the FAK
ÿ cells maintained a
rounded cell morphology. Despite the dierent appearance, both cell types formed numerous focal contact sites
which were visualized by indirect immuno¯uorescent staining of vinculin. The vinculin distribution was concentrated
in the cell periphery and these spots seem to be more abundant, but smaller in the FAK
ÿ ®broblasts compared to
the FAK
+ cells. The scale bar is010 mm.
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phenotypes of the SHP2 mutant and FAK knockout cells. They both exhibit a rounded
morphology, increased focal contact formation, and a disorganized cytoskeletal architecture
(Yu et al., 1998). In order to reconcile these observations, it may be necessary to view the
phosphorylation of FAK, p130
Cas, and paxillin within the context of a dynamic process.
Namely, that increased tyrosine phosphorylation per se may not be the critical factor for cell
migration events, but instead, repeated cycles of phosphorylation and dephosphorylation may
be essential for ecient coordinated cell movement. It is also possible that the inactive
phosphatase blockage of cell migration occurs at a dierent stage of the cell migration process
and that elevated FAK tyrosine phosphorylation events are unable to overcome this
impediment.
5.4. Pyk2 does not fully function to enhance FAK
ÿ cell migration
As discussed above and shown in a summary model (Fig. 9), Pyk2 expression is elevated in
the FAK
ÿ ®broblasts and Pyk2 functions in a compensatory manner in combination with Src-
family PTKs to facilitate FN-stimulated ERK2 activation in the absence of FAK. Interestingly,
whereas FAK primarily colocalizes with integrins at focal contacts, Pyk2 exhibited a punctate
peri-nuclear distribution in the FAK
ÿ cells and only weakly costained with vinculin-containing
focal contacts in the FAK
ÿ cell periphery (Sieg et al., 1998). These Pyk2 localization results
are in agreement with the perinuclear distribution of Pyk2 in rat ®broblasts (Sasaki et al., 1995;
Matsuya et al., 1998) and in rat smooth muscle cells (Zheng et al., 1998). With respect to
signaling events necessary for cell migration, FN-stimulation of the FAK
ÿ cells promoted
ERK2 activation to a level that was slightly less than that measured in the FN-stimulated
FAK
+ cells (Sieg et al., 1998). Although it is possible that this level of ERK2 activity is below
Fig. 9. Model of FN-stimulated signaling in the FAK
ÿ ®broblasts. In FAK
ÿ cells, Pyk2 expression is elevated,
however Pyk2 exhibits a predominant perinuclear distribution and does not strongly localize to focal contact sites.
FN stimulation of FAK
ÿ cells indirectly stimulates Pyk2 tyrosine phosphorylation through the activation of Src-
family PTKs. Although the connections between integrins and Src-family PTKs in the FAK
ÿ cells have not been
de®ned, Src-family PTK activity regulates FN-stimulated Shc tyrosine phosphorylation, Grb2 binding to Shc, and
ERK2 activation in the FAK
ÿ cells. The FAK
ÿ cells exhibit an elevated number of focal contact sites and the
FAK
ÿ cell migration defect may involve the inability to remodel these sites eectively in response to migratory
stimuli.
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stimulated ERK2 activity in the FAK
ÿ cells whereas only FAK but not Pyk2 eectively
promoted FAK
ÿ cell migration (Sieg et al., 1998). These results suggest that the defect in
FAK
ÿ cell migration does not involve signaling linkages to ERK2.
The inability of the FAK
ÿ cells to eciently migrate also may not involve linkages to
p130
Cas since Pyk2 is associated with p130
Cas in the FAK
ÿ cells (Ueki et al., 1998), p130
Cas is
tyrosine phosphorylated after FN stimulation of the FAK
ÿ cells (Vuori et al., 1996), and a
fraction of p130
Cas has been localized to FAK
ÿ focal contact sites (Nakamoto et al., 1997).
Since studies have shown that only a small fraction of overexpressed Pyk2 localizes to focal
contact sites in chicken embryo ®broblasts (Schaller and Sasaki, 1997), the inability of Pyk2 to
eectively promote FAK
ÿ cell migration may be related to its observed perinuclear
distribution in the FAK
ÿ cells. Thus, the ability of FAK but not Pyk2 to eectively stimulate
FAK
ÿ cell migration to FN may not be related to dierences in signaling pathways activated,
but instead it may involve the preferential localization of FAK-associated proteins to sites of
FN receptor clustering leading to the dynamic regulation of cell substratum contact sites.
5.5. FAK regulation of cell morphology
To date, many of the experimental results in support of a role for FAK in cell migration or
in the regulation of focal contact turnover events have been based upon either overexpression
analyses or conclusions extrapolated through the use of dominant-negative inhibitors. In
contrast, the FAK
ÿ ®broblasts can be considered as an excellent physiological model system
to test the essential role of FAK in the regulation of ®broblast cell shape and migration events.
As shown in Fig. 10, stable FAK re-expression in the FAK
ÿ cells led to dramatic changes in
cell morphology at both low and high cell densities. The FAK reexpressing ®broblasts
reassume a spread morphology identical to that observed in normal FAK
+ cells in
subcon¯uent densities and the FAK re-expressing cells form the characteristic ®brillar pattern
of primary ®broblasts at con¯uent densities (Fig. 10). In addition to the cell shape changes, the
FAK re-expressing cells exhibit elevated FN-stimulated migration rates compared to FAK
ÿ
cells and these migration rates are equivalent to that measured for normal ®broblasts (D. Sieg,
unpublished results). FAK also exhibits a dynamic distribution pattern in the re-expressing
cells showing costaining with actin at the leading edges in lamellipodial extensions in actively
spreading cells and costaining with vinculin-containing focal contact sites at the ends of actin
stress ®ber extensions in stably-spread cells (C.R. Hauck, unpublished results). These results
support the conclusion that FAK is directly functioning to promote migration and cell shape
changes within ®broblasts.
What functional sites on FAK are important for these events? Transient expression of
various FAK mutants in the FAK
ÿ cells have shown that kinase activity, SH2 binding at Tyr-
397, and SH3-mediated binding interactions at the ®rst proline-rich motif (Pro-712/713) all are
important for maximal FAK-enhanced cell migration events (D. Sieg, unpublished results).
FAK autophosphorylation at Tyr-397 and the recruitment of SH2 domain containing proteins
such as Src-family PTKs may be the ®rst of several sequential events important for FAK-
mediated cell migration. Secondary events such as the Src-mediated phosphorylation of
proteins associated with FAK via SH3 domain-mediated binding interactions at the ®rst FAK
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autophosphorylation creates a template for the binding of these or other signaling molecules,
and through unknown mechanisms, promotes the turnover of focal contacts thereby allowing
cell migration to proceed. As shown in the summary model (Fig. 11), FAK localization and
recruitment of Src-family PTKs to sites of integrin clustering functions to promote maximal
FN-stimulated signals to ERK2 through multiple Grb2-mediated pathways upstream of Ras.
Integrin-mediated ERK2 activation can enhance actin-myosin contractility events which
generates intracellular forces important for cell migration. In addition, the dynamic regulation
Fig. 10. Morphological reversion of FAK
ÿ ®broblast cell shape by stable FAK re-expression. Normal mouse
embryo ®broblasts (FAK
+/+, A and B), FAK-de®cient cells (FAK
ÿ/ÿ, C and D), or FAK-de®cient cells stably re-
expressing wild type FAK (FAK
ÿ/ÿ+FAK WT, E and F) were plated onto FN-coated dishes and phase contrast
pictures of the cells were taken after 12 h (A, C and E) or 72 h (13, D and F). The FAK
ÿ ®broblasts exhibit a
round morphology at low and high cell densities (C and D). FAK re-expressing ®broblasts appear morphologically
indistinguishable from normal primary mouse embryo ®broblasts at low cell densities (A and E) and exhibit a
characteristic ®brillar pattern at con¯uent cell densities (B and F). The scale bars are0200 mm.
D.D. Schlaepfer et al. /Progress in Biophysics & Molecular Biology 71 (1999) 435±478 470of tyrosine phosphorylation events at sites of integrin clustering also serves to modify the
linkages between integrin receptors and the actin cytoskeleton. In this way, FAK can be
envisioned to function at the junction of both FN-stimulated signaling and cell migration
events.
5.6. FAK overexpression in metastatic human tumors
In addition to its critical role in embryonic development and in ®broblast cell motility
events, FAK has been found to be overexpressed in a number of dierent human tumor
samples. Whereas in proliferative benign tumors there was no observed increase in FAK
mRNA levels (1/8) compared to normal tissue samples, a very high correlation was observed
between increased FAK mRNA levels in colon carcinomas of primary invasive (17/20) or
metastatic origin (15/15) (Weiner et al., 1993). The ®ndings were extended to the elevation of
FAK protein levels in colon and breast tumors that were in the process of becoming invasive
or had already demonstrated their capacity for invasion and metastasis (Owens et al., 1995).
High levels of FAK expression have also been found in preinvasive and invasive oral cancers
(Kornberg, 1998). In addition, a direct correlation has been made between increased FAK
expression and elevated cell motility in 6 dierent cell lines established from a primary human
malignant melanoma (Akasaka et al., 1995). It is possible that FAK overexpression may be a
common pathway for a variety of epithelial and mesenchymal tumor types to gain an invasive
potential. In addition, these observations indicate that increased FAK expression levels in
premalignant conditions may be useful as a marker for early cellular events leading to tumor
metastasis and raise the possibility that FAK might be a rational therapeutic target for the
disruption of the invasive process.
Fig. 11. Model of FN-stimulated signaling and cell migration in the FAK
+ ®broblasts. In FAK
+ ®broblasts,
FAK localizes to sites of integrin clustering and can promote intracellular signal transduction events. The combined
action of FAK and Src-family PTKs facilitates integrin signaling to the Ras-ERK2 cascade through multiple Grb2
binding interactions with FAK and Shc. Targets for activated ERK2 in the FAK
+ cells include myosin light chain
kinase (MLCK) and transcription factors in the nucleus that can aect gene transcription events. The FAK-
mediated recruitment of signaling proteins such as p130
Cas (Cas) to sites of integrin clustering and the dynamic
regulation FAK-associated tyrosine phosphorylation events also promotes the remodeling of cell substratum
contacts sites (through unknown mechanisms) leading to enhanced cell migration.
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In this review, we have focused on the connections between integrins and FAK-mediated
signaling events. One of the best analogies to describe the role of FAK in cells is that it
functions as a `scaold' for the assembly of signaling complexes through the coordinated
recruitment of other signaling and adaptor proteins. One important but yet undetermined
aspect of FAK function is whether the proteins associated with FAK in promoting cell
migration events are the same or dierent from those associated with FAK in delivering signals
important for cell survival. It is also becoming clear that FAK can become activated by stimuli
other than integrin receptor clustering events. This puts FAK in a position to modulate or
contribute to signaling cascades activated by both integrins and other cell surface receptors.
Future eorts to determine and decipher the interactions between FAK and other signaling
proteins will continue to enhance our knowledge on the regulatory mechanisms of cell growth,
shape, and migration.
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